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List of abbreviations  
Aβ     β-Amyloid 
Aβ40    β-Amyloid peptide of 40 residues in length 
Aβ42    β-Amyloid peptide of 42 residues in length 
AD     Alzheimer’s disease 
AFM    atomic force microscopy 
APP  amyloid-precursor protein 
BAEE N-benzoyl-L-arginine ethyl ester 
BBB    blood-brain barrier 
CA   caffeic acid 
CGA    chlorogenic acid 
CR     Congo red 
ECD  electronic circular dichroism 
EGCG    epigallocatechin-3-gallate 
EM     electron microscopy 
FDA  Food and Drug Administration 
FTIR  fourier-transformed infrared 
GA  gallic acid 
GC  gallocatechin 
hIAPP    human amylin or human islet amyloid polypeptide 
MCI  mild cognitive impairment 
MD     molecular dynamics 
MTT    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NFT    neurofibrillary tangle 
NMR    nuclear magnetic resonance 
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(PAP)248-286   phosphatase-cleaved amyloid precursor peptide 
PMSF phenylmethylsulfonyl fluoride 
SDS-PAGE  sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEC  size exclusion chromatography 
SSNMR    solid-state nuclear magnetic resonance 
tau 2N4R    isoform of human tau containing 4 microtubule binding domains and 2 
amino terminus inserts 
TEM    transmission electron microscopy 
ThT     thioflavin T 
UV-Vis  ultraviolet-visible (light) 
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1. Introduction 
One of most remarkable phenomena of nature is the ability of proteins to fold from 
linear polypeptide chains into functional structures serving as molecular machines that are 
indispensable for living organisms (Dill et al., 2008).  Proteins are essential in many areas 
of life. They play a remarkable role as structural material. They act as structural scaffolds, 
catalyze biochemical reactions, regulate cell cycles, carry out transport and storage in 
living cells, and are essential elements of many signal transduction pathways (Ardito et 
al., 2017). 
There are about 24,500 protein-encoding genes in the human genome (Clamp et 
al., 2007). Proteins consist of amino acid residues linked by peptide bonds. Protein folding 
is a rather complicated process; the details of it have not been fully understood yet. A 
failure at folding may lead to illness (Raimondi et al., 2017). Sometimes misfolding 
results in harmful aggregation. Molecular chaperones prevent incorrect folding and 
aggregation (Hendrick and Hartl, 1995). The misfolding of protein and their aberrant 
assembly into unbranched amyloid fibrils have been paid great attention (Siddiqi et al., 
2017). The structural knowledge of protein aggregation will be significantly expanded in 
the next decades (Hu, 2017). Protein misfolding and aggregation cause a lot of illnesses 
(Khan et al., 2017). Amyloid fibrils with an ordered characteristic cross-beta structure 
appear in numerous neurodegenerative diseases (Dobson, 2017). At present, it is known 
that the appearance of amyloid fibrils is an indicator of various central nervous system 
neurological disorders and neurodevelopmental diseases affecting the brain and peripheral 
tissues (Stefani and Rigacci, 2013; Kim et al., 2013). Amyloid is a generic structural form 
of proteins and peptides and most polypeptides can form amyloid-like fibrils under 
suitable conditions (Chiti et al., 1999). The propensity of non-disease associated proteins 
to form pathological amyloid fibrils depends on their amino acid sequence (Siddiqi et al., 
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2017). The core structure of the amyloid fibrils is stabilised by hydrogen bonding between 
the atoms of the polypeptide backbone (Dobson, 2003). Whereas various proteins are 
responsible for each disease, it is true for each that they have -sheet-rich secondary 
structures and fibrillar aggregates in common (Šneideris et al., 2015). The formation of 
insoluble amyloid fibrils is associated with various incurable medical conditions, such as 
Alzheimer’s, Huntington’s and Parkinson’s disease, transmissible spongiform 
encephalopathy, cerebellar ataxia, primary and secondary systemic amyloidosis and type 
II diabetes mellitus (Stefani, 2004; Bieschke, 2013).  
The search for therapeutic agents that inhibit amyloid formation is a major 
challenge today (Young et al., 2015; Ma et al., 2018). For many chronic illnesses, 
prevention is more effective than treatment. Functional foods contain more biologically 
active ingredients, that have received remarkable attention, not only in traditional but in 
modern medicine. Natural phenolic compounds, which make up a long family of plant 
substances, are one of the most actively investigated categories of potential anti-amyloid 
drugs (Stefani and Rigacci, 2013; Shariatizi et al., 2015). There are currently more than 
8,000 plant polyphenols and among them there are more than 4,000 flavonoids 
(Karunaweera et al., 2015). Human beings have been using various spices for more than 
2,000 years, even so studying their biological activities has only begun today. Spices can 
prevent neurodegenerative processes (Mirmosayyeb et al., 2017). 
 
1.1. The amyloid state of proteins 
Amyloids were defined more than 150 years ago when tissue deposits of 
extracellular filaments were observed in the body’s different organs. These microscopically 
visible deposits were found on different organs in many seemingly unrelated diseases, both 
systemic and localized in the body (Sipe and Cohen, 2000; Haass and Selkoe, 2007). 
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Although many diseases involve amyloid formation of distinct aggregation-prone proteins 
or peptides, the ability to form amyloid is not limited to these disease-associated proteins 
only. Amyloid fibrils may be formed from proteins, which can also fold into well-defined 
tertiary structures (for instance myoglobin and lysozyme) suggesting that the ability to 
form amyloid fibrils may be a general property of polypeptides. However, the main 
propensity for a particular protein or peptide to form amyloid fibrils is largely dependent 
on amino acid sequence. This is because for a globular protein to adopt an amyloid state, it 
has to be partly unfolded first before becomes into an amyloid fibril (Chiti and Dobson, 
2006). Under suitable circumstances protein can convert into harmful aggregates. 
Disordered aggregates can be form from partially folded states. These unstable aggregates 
can convert ordered amyloid fibrils through more stable β-structured aggregates. Amyloid 
fibrils are thread-like structures with 7 to 13 nm diameter, containing 2-8 protofilaments in 
them twisted around each other. β-strands in fibrils are perpendicular to the long axis of the 
fibrils. If the amorphous deposits and native-like deposits form in an uncontrolled manner, 
these are also associated with pathological conditions (Fig. 1). Amyloid fibrils are formed 
by a nucleated polymerization mechanism. Their formation follows sigmoid kinetics with a 
lag phase, growth phase and saturation phase. In the lag phase disordered monomers 
convert into nuclei, fibrils and then they grow by addition of monomers fast (Chiti and 
Dobson, 2017) (Fig. 2). Experimental data suggest that critical protein concentrations are 
required to initiate fibrillation (Blancas-Mejía et al., 2017).  
Amyloid aggregates are not soluble in the presence of detergents (Nizhnikov et al., 
2014). Thioflavin-T (ThT), a benzathiole dye, is more commonly used to identify the 
presence of amyloid fibrils, as its fluorescence emission increases when it binds to the 
fibrils (Nilsson, 2004). 
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Figure 1. Multiplicity of conformational states (Chiti and Dobson, 2017). IDPs: 
Intrinsically disordered proteins. 
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Figure 2. Nucleation dependent amyloid fibril formation (Iannuzzi et al., 2014). 
 
1.1.1. Amyloid fibrils 
Fibrillar amyloid deposits have more physical properties in common. Most 
importantly, they exhibit specific optical behaviors when linked to certain dye molecules. 
Fibrils show green birefringence under polarized light after being staining with Congo red 
(Frid et al., 2007). However, the use of Congo red to detect the presence of amyloid is 
frequently a labor-intensive process, and only provides a quality measurement of amyloid 
fibrils present.  
In addition to binding to fibrils, ThT has both dramatic and standard enhancement 
of its emission and a maximum shift of its excitation spectrum, which show the presence of 
amyloid fibrils as an effective and efficient indicator (Nilsson, 2004). 
Amyloid fibrils formed from various polypeptides are believed to share a similar 
morphology known as the cross-β structure (Chiti and Dobson, 2006). Independent 
measurements of the fibrillary structure have so far confirmed the cross-β structural core of 
amyloid fibrils. X-ray fiber diffraction studies have shown that the diffraction pattern of 
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fibrils is characterized by main orthogonal reflections along the meridional and equatorial 
directions corresponding to a 4.8 Å inter-peptide separation, and a 10 Å inter-sheet 
separation respectively (Sipe and Cohen, 2000; Nilsson, 2004; Sunde et al., 1997) (Figure 
3).  
 
Figure 3: The cross-β structure and the diffraction pattern of fibrils (Eisenberg 
and Jucker, 2012). 
 
The separations between the inter-peptide and the inter-sheet are parallel and 
perpendicular to the long-axis of the fibril. This diffraction pattern is now regarded as 
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indicative of the presence of cross-β structure, and thus the presence of amyloid fibrils. 
When fibrils are stained, the macromolecular morphology of fibrils could be determined by 
the transmission electron microscopy (TEM): fibrillary structures are long, non-branched, 
and ribbon-like structures (Chiti and Dobson, 2006) (Figure 4). The typical diameter of 
amyloid fibrils is  10 nm and a length up to a few micrometers (Petkova et al., 2002). 
 
 
Figure 4: TEM image of negatively-stained Alzheimer’s Aβ fibrils. The scale bar is 200 
nm (Gras et al., 2011). 
 
Over the last decade, the progress of solid-state NMR (SSNMR) and X-ray 
crystallography explained the molecular atomic details of amyloid fibrils. One of the first 
SSNMR models of an amyloid fibril used was that of Aβ40, a peptide affected by 
Alzheimer’s disease. Its core fibril unit consists of a parallel in-register β-sheet, wherein 
each strand is a β-hairpin peptide-peptide backbone with hydrogen bonds which run 
parallel to the long-axis of the fibril (Petkova et al., 2002; Petkova et al., 2006).  
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The individual packing arrangement of polypeptides in amyloid fibrils may change 
with the changing experimental conditions in which the fibrils are formed. The especial 
structural polymorphism includes the length of the β-strands, side chain orientations and 
inter-proto filament packing (Kodali and Wetzel, 2007). Fibril polymorphism may play an 
important role in amyloid diseases, as the various morphologies show different toxic effect 
depending on which residues are exposed on the surface. For instance, they have been 
shown that calmly formed fibrils of Aβ(1-40) to be more toxic than agitated fibrils 
(Petkova et al., 2005).  
 
1.1.2. Non-fibrillar oligomers 
Due to their structural disorder and transient nature, it is difficult to obtain high 
resolution structural details of amyloid oligomers, using conventional normal structural 
determination techniques. Studies in TEM and atomic force microscopy (AFM) using low-
resolution techniques have shown that transient, unstable particles may appear before the 
formation of fibrils (Chromy et al., 2003; Caughey and Lansbury, 2003; Kayed et al., 
2003). These protein aggregates are mentioned in the literature as amyloid proto fibrils 
(Chiti and Dobson, 2006). Those that do not progress to form fibrils are regarded off-
pathway. Nevertheless, off-pathway oligomers formed in the presence of detergents, lipids, 
and certain small molecules are generally ignored to be biologically-relevant. Contrary to 
fibrils, amyloid oligomers do not have a generic structural element and instead, they have a 
wide spectrum of sizes and morphologies. Size exclusion chromatography (SEC) studies of 
Aβ40 oligomers (isolated in vitro from the brains of persons who died of Alzheimer’s 
disease) have shown the existence of oligomers ranging from dimer size to big oligomers 
of hundreds of peptides. Annular, spherical, or curvilinear oligomeric assemblies in shape 
have been published in literature (Kayed et al., 2003; Chimon et al., 2007).  
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Although there are big differences in morphologies, oligomers formed from 
different polypeptide sequences may exhibit similar activities during cell metabolic assays. 
It is important to note that many oligomers of different sizes always share the ability to 
interact with a single oligomer-specific antibody. Numerous studies have shown that 
oligomers can have high β-sheet content (Walsh et al., 1999; Chimon et al., 2007; 
Campioni et al., 2010). In addition, some non-fibrillar oligomers may contain common 
structural elements. Based on the high-resolution structural analysis of non-fibrillar 
oligomers of Aβ42 and of prion-like peptides, it is assumed that they may contain cross-β 
like fragments (Stroud et al., 2012; Walsh et al., 2010). 
 
1.2. Amyloid involvement in diseases 
All proteins may form unbranched, long, amyloid fibrils with many beta-sheets in 
vitro under suitable conditions i.e., formation of amyloid might be a general property of the 
polypeptide backbone (Simon et al., 2012; Dorta-Estremera et al., 2013; Kotormán et al., 
2017). The aggregation behavior of various peptides and proteins shows remarkable 
similarities. Unfolded or partially unfolded proteins connect to each other forming small, 
soluble aggregates that undergo further assembly into proto fibrils or proto filaments. 
These structures are usually short, thin, in some cases curved, fibrillar structures that can be 
assumed to compile into mature fibrils. In vitro experiments suggest that the formation of 
such species will generally begin with a lag phase, followed through rapid growth. This 
phenomenon is increasingly associated with common and highly debilitating diseases.  
As numerous diseases share the amyloid plaque pathology and toxicity, fibrils were 
originally hypothesized to be the toxic species in these diseases (Hardy and Selkoe, 2002). 
However, recent research has shown that non-fibrillar oligomers are more likely to be the 
toxic agents causing multiple neurodegenerative diseases (e.g., Parkinson’s, Alzheimer’s, 
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Huntington’s diseases and spongiform encephalopathies) and type II diabetes (Xue et al., 
2009; Berthelot et al., 2013). At present, the mechanism of toxicity of amyloid oligomers 
has not been identified, and it is an area under intensive research. Oligomers formed from 
many peptides, including those not related to amyloid disorders (e.g. lysozyme, β2-
microglobulin, transthyretin), all exhibited toxicity, which suggests that the toxicity of 
amyloid oligomers may be independent of the peptide sequence (Kayed et al., 2003; 
Fändrich, 2012). Experimental evidence broadly supports the hypothesis that amyloid 
toxicity is based on a generic mechanism involving the interactions of oligomers with 
cellular membranes and other compounds (Martins et al., 2008). Specifically, it is assumed 
that oligomeric aggregates may at last induce cell death by interacting with and disrupting 
the integrity of the cellular membrane (Berthelot et al., 2013). Moreover, the aggregation 
of amyloidogenic peptides was found to occur faster in the presence of membrane surfaces, 
which lead to the claim that membrane-catalyzed fibril formation may cause cellular 
toxicity. 
Diseases related to amyloid fibrils (Table 1) can be classified as degenerative 
diseases (for instance Alzheimer’s disease) and prion diseases (for instance bovine 
spongiform encephalitis). Prions cause the formation of amyloid fibril in vivo in other 
systems (Scott et al., 1999; Hill et al., 1997). In some amyloid-related illnesses, patients 
die because of organ failure resulting from amyloid fibril deposits (Siqueira-Filho et al., 
1981).  
There is no simple way to treat amyloid diseases. Currently, it is limited to treating 
the symptoms of illnesses. Although some forms of amyloidosis can be treated by 
chemotherapy and organ transplantation, large amyloid fibril masses can only be removed 
surgically (Pepys, 2006).  
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Table 1: A list of some amyloid associated diseases and their precursor 
polypeptides (Ow and Dunstan, 2014).  
 
 
1.3. Alzheimer’s disease 
Alzheimer’s disease (AD) was first described in 1907 by a German physician 
named Alois Alzheimer. It is a progressive neurodegenerative disorder (Hippius and 
Neundörfer, 2003). AD is the most common cause of dementia in elderly people, 
accounting for 60-70% of cases (Fratiglioni et al., 2000). Age is the most significant risk 
factor for AD, the prevalence for the disease is around 1% at age 65 and around 20% at 85 
Precursor polypeptide Amyloid classification Associated syndrome/disease 
Aβ peptide Aβ Alzheimer’s disease 
Atrial natriuretic factor AANF Cardiac arrhythmias 
Serum amyloid A protein AA Rheumatoid arthritis 
Apolipoprotein A1 AApoA1 Atherosclerosis 
Cystatin C Acys Cerebral amyloid angiopathy 
(Icelandic type) 
Gelsolin AGel Familial Finnish amyloidosis 
Immunoglobulin light chain AL Systemic Al amyloidosis 
Islet amyloid polypeptide AIAPP Diabetes mellitus, type II 
Kerato-epithelin Aker Lattice corneal dystrophy 
Lysozyme Alys Hereditary non-neuropathic 
systemic amyloidosis  
Median AMed Aortic medial amyloid 
β2-Microglobulin Aβ2M Dialysis related amyloidosis 
Prion protein APrP Spongiform encephalopathies 
Prolactin APro Prolactinomas 
Transthyretin ATTR Familial amyloid polyneuropathy 
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years of age. Upon investigation, the postmortem brains of AD patients show significant 
neuronal dystrophy. With the growing old population of the world the number of AD 
patients will tremendously increase and with it the economic cost to be paid by society. 
From a pathological point of view, AD is characterized by the presence of extracellular 
deposits of senile plaques and neurofibrillary tangles (NFTs), each of which appear as 
lesions on stained neuronal tissue under visible light microscopy (Figure 6). The global 
prevalence of dementia was estimated at 24 million and is predicted to double every 20 
years by at least 2040. As the world’s population is constantly aging, the number of 
vulnerable individuals is growing, especially among the very old. The disease is closely 
linked to aging and it has been estimated that around 81.1 million people worldwide will 
suffer from AD by 2040 (Ferri et al., 2005; Mayeux and Stern, 2017). 
 
Figure 6: Lesions in the cerebral cortex tissue of an AD brain formed from amyloid 
plaques and NFTs (Blennow et al., 2006). 
 
The first symptoms of AD are often loss of short-term memory, and, with the 
progression of the disease, disorientation and aphasia followed by a general decrease in 
cognitive functions. 
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Despite the fact that there are different tests and criteria available for clinical 
diagnosis, a definite AD diagnosis can only be made post mortem by a pathological exam 
of the brain to check the existence of the aforementioned neuropathological changes. 
AD has three clinical disease stages: pre-symptomatic, prodromal or amnestic or 
non-amnestic mild cognitive impairment (MCI) and AD dementia. The pre-symptomatic 
stage comprises of a cognitively normal person that have begun to develop the pathological 
features of AD, amyloid plaques and NFTs. The next stage, MCI, the appearance of 
cognitive symptoms, often deficits in episodic memory with amnestic MCI and attention or 
language with non-amnestic MCI and may include some progress in cognitive dysfunction. 
This stage may also be associated with irritability, anxiety and depression. The last stage of 
dementia, as defined above, consists of impairments in several cognitive domains, such as 
executive functions, language, and visuospatial functions. At this stage, behavioral changes 
such as aggression, agitation, emotional distress, restlessness, and sleep disturbance may 
appear. Patients are mostly diagnosed in the MCI stage as their concerns about changes in 
cognition increase. The disease course generally lasts from 3 to 8 years depending on the 
age of the patient at diagnosis (Cappai and Barnham, 2008), out of which ~40% of the time 
is spent in the most severe stage of the disease (Arrighi et al., 2010). 
Patients with illness can usually be divided into two subgroups depending on the 
age of beginning. The initial AD, which accounts for about 2% of all AD cases, occurs 
before the age of 65 whereas the more frequent form, late onset AD called sporadic, 
appears after the age of 65. Familial AD belongs to the group of the early AD group of AD 
and is caused by amyloid-precursor protein (APP), Presenilin 1 or Presenilin 2 mutations. 
In 1985, the amyloid-β protein or Aβ was identified as the major constituent of 
these senile plaques. Monomer Aβ is about 4 kDa peptide which is produced by the 
intramembrane proteolytic cleavage of a bigger protein, the APP (Hardy and Selkoe, 2002). 
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APP is sequentially processed with aspartyl proteases β-secretase and γ-secretase, 
producing a set of Aβ peptides of lengths varying from 38 to 43 residues depending on the 
position of the cleavage with γ-secretase (Figure 7) (Gandy, 2005).  
 
Figure 7: A schematic representation of the production of Aβ through proteolytic 
processing of APP (Sumner et al., 2018). 
 
Peptides containing residues 1-40 (Aβ40) or 1-42 (Aβ42) are predominantly found 
in AD-associated plaques (Golde et al., 2000; Holtzman et al., 2011). Although the plaques 
contain various isoforms of the Aβ peptide, Aβ42 is likely to be the more harmful form of 
Aβ. In vitro, Aβ42 exhibits a significantly higher propensity for aggregation compared to 
Aβ40, despite the fact that only two amino acids differ from each other (El-Agnaf et al., 
2000; Barrow et al., 1992).  
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Furthermore, genetic mutations within presenilin 1 and 2 (genes encoding enzymes 
that cleave APP to produce Aβ peptides) also cause an aggressive early-onset form of AD, 
leading to an increase in the ratio of Aβ42 to Aβ40 peptides produced (Kumar-Singh et al., 
2006; Bentahir et al., 2006; Hardy, 1997). Genetic evidence strongly supported the 
amyloid hypothesis: a chromosome responsible for APP encoding in trisomy 21 (Down’s 
syndrome), and the overproduction of Aβ causes an early-onset of dementia with AD-like 
plaque load (Goate et al., 1991; Levy-Lahad et al., 1995). Additionally, in individuals with 
early-onset familial AD, genetic mutations on the APP induce the production of Aβ 
peptides that exhibit an increased aggregation tendency (Tam and Pasternak, 2012).  
In addition to the presence of amyloid plaques, the other marker of AD is the 
intracellular deposition of NFTs which consists of aggregated hyper phosphorylated forms 
of the microtubule-associated  protein (Ballatore et al., 2007). The role of the  protein 
and interaction of the amyloid in AD pathogenesis is still established (Ittner and Götz, 
2011). Investigations with mouse models suggest that the role of NFTs in AD may be 
lower than Aβ since Aβ plaque pathology was not developed in a  transgenic mouse 
model, whereas Aβ formation in APP transgenic mice was found to induce hyper 
phosphorylation of , leading to the formation of NFTs (Götz et al., 2004). 
 
The mysterious aspect of AD is that in the brain of dementia patients, plaque load 
does often not correlate with the progression and severity of the disease (Stroud et al., 
2012; Näslund et al., 2000). Instead, more pieces of evidence show that the synaptic loss 
and the severity of cognitive impairment are correlated with the concentration of soluble 
Aβ oligomers in the brain (Lue et al., 1999). For instance, oligomers extracted from AD 
brain may damage synapse structure and function. Furthermore, when injected into the 
brains of animal models of AD, Aβ oligomers reduced the number of synapses and 
decreased learning ability (Lesné et al., 2006; Cleary et al., 2005). In addition, cellular 
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models of toxicity exhibited characteristic symptoms of neurotoxicity that lead to possible 
apoptosis by adding of Aβ oligomers prepared either in vitro or extracted from cell cultures 
(Cappai et al., 2008). In summary, current experimental evidence suggests that preventing 
the formation of Aβ oligomeric forms is a promising method of the treatment for AD. 
 
1.4. Amyloid inhibition by small molecules can be a promising method for treating for 
AD. 
With the increasing lifespan of our population, AD approaches epidemic 
proportions and there is no cure or preventive treatment. In 2010, it was estimated that 36 
million people in the world were suffering from AD, and this number is expected to grow 
to 115 million people by 2050 (Alzheimer’s Association, 2012). Compounds have been 
reported to help the reduction of amyloid deposition in the brain either by inhibiting the 
enzymes or by inhibiting Aβ peptide aggregates using of antibodies, small peptides, or 
small organic molecules, natural product extracts, or by increasing amyloid degradation 
using amyloid vaccines. 
Furthermore, there are no drugs that can target the underlying disease: currently 
licensed treatments such as donepezil (a cholinesterase inhibitor), and memantine (an N-
methyl-D-aspartate antagonist), only mitigate cognitive symptoms. At present, five drugs 
are approved by the Food and Drug Administration (FDA) for use at AD cases and are 
divided into two categories: acetylcholinesterase inhibitors and glutamate modulators. All 
five drugs were licensed between 1993 and 2003, none address the underlying etiology of 
AD, and their effectiveness differs greatly among individuals. During the first year, the 
performance of a patient can be significantly improved in measures of cognition, activities 
of daily living behavioral symptoms, and clinical global impression of change for 10−20% 
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of patients, plateau for 30−50% of patients, or continue to deteriorate for 20−40% of 
patients (Atri, 2011). 
Although AD does not currently have therapeutics, progress has been made. 
Intensive structural and biochemical analysis of the amyloid structure has led to the 
development of potential therapeutics for treating underlying diseases. In the last years, 
small-molecule compounds have been developed that reduce the formation, deposition and 
accumulation of Aβ amyloid aggregates as a promising method of AD treatment. In vitro 
screenings led to the discovery of many small molecules that may affect the amyloid 
aggregation pathway (Ryan et al., 2012). Some of these drug-like molecules inhibit the 
formation of amyloid fibrils, while others prevent or reduce non-fibrillar oligomer 
formation (Levine, 2007; Necula et al., 2007).  
The most important pharmacological requirement of drugs targeting AD and other 
neurodegenerative diseases is their ability to penetrate the blood-brain barrier (BBB) at 
appropriate concentrations in the brain to effectively reach their therapeutic effects (i.e., to 
inhibit amyloid formation) (Hawkes et al., 2009; Hubbard, 2011). Although many small 
molecules prove to be effective in inhibiting amyloid formation in vitro and amyloid 
toxicity in cell cultures, many of these small molecules have poor BBB penetration and are 
very toxic, and therefore not readily used as genuine therapeutics. 
 
1.4.1. Dye-based molecules 
Among the first compounds that bind amyloid fibrils are the dye molecules used to 
identify amyloids (Figure 8). Congo red (CR) was initially used for the histological 
detection of amyloid binding, where fibrils exhibit red-green birefringence when bound to 
CR if viewed with polarized light (Frid et al., 2007). The binding affinity of CR is within 
the range of 0.1 - 1.5 µM for different fibrils. Like CR, ThT shows Kd’s in the low µM 
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range, with values ranging from 0.033 to 23 µM published in the literature (Groenning, 
2010). 
 
 
Figure 8: Chemical structure of amyloid-binding dyes Congo red and its derivative, 
Chrysamine G. 
 
However, although ThT is closely bound to amyloid fibrils, binding has not been 
found to affect amyloid aggregation, unlike CR. Early amyloid detection using CR showed 
that CR is not only bound to fibrils but may also affect the amyloid aggregation pathway 
by interacting with one or more amyloidogenic species (Caspi et al., 1998). The fibril 
formation of amyloidogenic Aβ fragments, prion proteins, and the immunoglobulin light 
chain variable domain have been found to be promoted by the presence of CR at low molar 
ratios, and inhibit at high molar ratios (Esler et al., 1997). 
Although CR has anti-amyloidogenic and anti-prion properties, its carcinogenic 
properties make CR a poor therapeutic candidate (Hawkes et al., 2009). Therefore, efforts 
have been made to find CR-based analogues that maintain anti-fibrillar aggregation activity 
but have improved toxicity profile and BBB bioavailability. Chrysamine G (CG) is one 
such analogue of CR (Figure 8). CG exhibits higher lipophilicity and lower toxicity than 
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CR and is able of inhibiting aggregation and amyloidogenic toxicity both in vitro and in 
vivo (Ishii et al., 2002; Reinke and Gestwicki, 2007).  
 
1.4.2. Polyphenols 
Polyphenols are a class of molecules naturally occurring in plants, and contain one 
or more aromatic phenolic rings with more hydroxyl groups (Figure 9 and 10).  
 
 
 
 
 
 
Figure 9. Chemical structures of identified flavonoid natural product-based amyloid 
inhibitors (Velander et al., 2017). 
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Figure 10. Chemical structures of identified phenolic natural product-based amyloid 
inhibitors (Velander et al., 2017). 
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Due to their antioxidant properties, the consumption of polyphenols has been 
reported to have a beneficial effect on health. For instance, epigallocatechin-3-gallate 
(EGCG), a main phenolic component of green tea and resveratrol, a polyphenol present in 
red wine, has cancer-preventing properties (Baur and Sinclair, 2006; Singh et al., 2011). In 
the last years, polyphenols were given more attention due to their ability to treat AD (Porat 
et al., 2006). 
Furthermore, based on their various functions including anti-oxidant, anti-
inflammatory, metal chelating capacities, polyphenols provide a rich source for many 
different structural backbones to find multifunctional anti-amyloid agents that can be used 
in rational drug planning efforts (Savelieff et al., 2014; Korshavn et al., 2016). 
Examples include oleuropein and oleocanthal are present in olive oil, resveratrol is 
in fruit and red wine, curcumin is in turmeric, as well as EGCG and myricetin is in green 
tea. Other polyphenols found in healthy foods comprise cinnamaldehyde found in 
cinnamon, caffeic acid and rosmarinic acid found in culinary herbs, and genistein found in 
legumes. Contrary to the flavonoids or phenolic acid derivatives that included the majority 
of structures found within polyphenol amyloid inhibitors, many inhibitors with remarkable 
various structures were identified: cyclodextrin, a cyclic carbohydrate byproduct formed 
from enzymatic starch degradation; squalamine, an aminosterol isolated from dogfish with 
previously documented antiviral and anti-bacteria effects (Savelieff et al., 2014; Korshavn 
et al., 2016); vitamin A, a fat soluble vitamin (Takasaki et al., 2011); hematin, a porphyrin 
used in treatment of porphyria (D’Avola et al., 2016); rifampicin, an antibiotic for the 
treatment of bacterial infections; and scyll-inositol, a plant sugar alcohol there is plenty in 
coconut palm. Attention should be paid to the fact that the amyloid-inhibitory functions of 
many of these compounds have not been validated in vivo. 
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1.5. Recent results in elucidating the molecular mechanism of small-molecule binders 
and inhibitors of amyloidogenic species 
Amyloid fibril formation is a multi-stage process involving various species at each 
stage. Because of the heterogeneous nature of prefibrillar species, the experimental 
determination of the molecular structures of these amyloid species remains a challenge. 
Further compounding experimental challenges, these small molecules can interact with 
amyloidogenic species at various stages of aggregation that are not known a priori. In 
addition, the binding mechanism of small molecule amyloid aggregation inhibitors is not 
fully described by the classical enzyme-inhibition model. The observation of amyloid 
inhibition often requires an inhibitor concentration in the micro-molar to milli-molar range 
(Hawkes et al., 2009), which suggests that these small-molecule inhibitors are non-specific 
binders. In contrast, substrates of folded enzymes have higher binding specificity, their 
binding affinities are often in the nanomolar range (Singh et al., 2011). In summary, the 
above-mentioned challenges significantly inhibited the determination of the molecular base 
of amyloid inhibition by using experimental methods with small-molecule inhibitors. 
In contrast, computer simulations are not limited by these experimental challenges, 
and are able to give the atomistic level of details required to clarify the effect of small 
molecules in inhibiting of amyloid formation. Because of these molecular dynamics (MD), 
simulations have played a key role in understanding the binding mechanism of these small 
molecule inhibitors. However, clarification of the molecular basis of these small-molecule 
inhibitors poses many difficulties for simulation studies. The structural disorder of 
amyloid-forming peptides makes statistically meaningful attributes of MD simulations 
difficult. Furthermore, since it is unknown whether small-molecule inhibitors can interact 
with amyloidogenic monomers or aggregates, their binding should be frequently studied 
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with a number of amyloidogenic species in order to fully understand their mechanism of 
action. 
With the combination of isothermal titration calorimetry, NMR, and MD 
simulations, the interaction of EGCG molecules with monomeric Aβ42 as modulated by 
temperature, salt concentration, pH, and ligand: protein molar ratio was examined by Wang 
et. al (Wang et al., 2010). The simulations were performed in the presence of EGCG by 
increasing molar ratio of the Aβ peptide in α-helical conformation. The results of this study 
showed that both hydrogen bonding and hydrophobic (aromatic) interactions are important 
for EGCG binding, and the balance of these interactions is especially sensitive to ligand: 
protein stoichiometry. 
 
1.6. Drug discovery strategies against amyloid related disorders 
 
Several therapeutic strategies are used to identify disease modifiers against amyloid 
related disorders. To identify the natural compound, the source of information is derived 
from epidemiological studies suggesting preventive effects for AD, dementia or diabetes 
may be associated with diets that contain high intake of polyphenolic compounds and 
flavonoids (Wang et al., 2010). The Mediterranean diet, characterized by a high intake of 
fruits, vegetables, olive oil, and cereals, is associated with reduced risk for mild cognitive 
impairment and AD in multiethnic community studies in New York (Scarmeas et al., 2006; 
Scarmeas et al., 2009). According to several cohort studies, moderate intake of red wine 
(which contains resveratrol) is associated with reducing the risk of AD, dementia, or 
cognitive decline (Arntzen et al., 2010; Luchsinger and Mayeux, 2004). Curcumin, present 
in yellow curry spice, EGCG and myricetin, polyphenolic compounds found in green tea, 
and turmeric found in traditional Southeast Asian diets are associated with cognitive 
functional health (Yamada et al., 2015). However, the protective effects of the food are not 
 29 
 
the same as the specific effects of a single active ingredient. It is not known how diet 
specific natural compounds may have an effect on health. However, information reported 
by alternative and complementary medicine and information from these epidemiological 
sources resulted to testable hypotheses and experimental efforts which have successfully 
identified a number of natural amyloid inhibitor compounds (Ardah et al., 2015; Rigacci et 
al., 2010; Ono et al., 2004; Velander et al., 2016). One of the current strategies for 
identifying therapeutic lead compounds for amyloidosis focuses on inhibition of amyloid 
aggregation, inhibition of toxic amyloid formation and/or stabilization its native form from 
aggregation and degrading or remodeling toxic amyloid oligomers and/or insoluble fibrils. 
Different approaches were applied. Several platforms, including in vitro (Chen et al., 2010) 
and cell-based approaches (Kim et al., 2006), were applied in a semi-to-high throughput 
capacity to screen for small molecules that modulate or prevent amyloid aggregation. 
One selection criterion used to choose the library of compounds for screening 
emphasizes the overall diversity and quantity of compounds not the specific underlying 
physicochemical characteristics (Chen et al., 2010). For example, Chen et al. developed a 
high throughput small molecule microarray assay which can be used for identifying 
amyloid inhibitors by judging binding affinity with amyloid β-peptide with ~11,000 
various small molecule leads per array slide. Activities were evaluated from several natural 
and synthetic compounds and diversity-oriented synthetized compounds. Numerous high-
resolution crystal structures of the fragment of amyloidogenic protein sequences are in 
accordance with atomic structural analysis on small molecules binding these structures 
(Wiltzius et al., 2008; Nelson et al., 2005) revealing many molecular scaffolds that either 
modulate or inhibit the formation of amyloid. These structures, some of which are 
potentially recommended as potential pharmacophores that can presumably target the 
generic cross β spine architecture common to all amyloids, are being used for structure-
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based drug design efforts at present. For instance, Eisenberg’s group, uses amyloid binding 
dye, Orange G, generated a high throughput screening platform that uses experimental 
approaches and iterative computational, and examined and fine-tuned structure activity 
relationships for lead compounds with optimum activity against Aβ amyloid (Landau et al., 
2011). Furthermore, working with molecular dynamics and molecular docking simulation 
is a common approach to screen small molecule libraries, getting mechanistic insights into 
drug – target interactions, and optimizing lead compounds (Lemkul and Bevan, 2012; 
Lemkul and Bevan, 2012).  
 
1.6.1. Mechanism of inhibition 
The particular stages of aggregation and amyloid species that are targeted by 
natural product-based inhibitors, and as a result biomolecular and biochemical processes, 
associated with amyloid induced cytotoxicity, have not been fully discovered yet. 
However, a detailed understanding of the chemical mechanisms underlying these processes 
has recently been clarified. Anti-aggregation or anti-amyloidogenic agents can form 
covalent bonds (Sato et al., 2013; Zhu et al., 2004; Palhano et al., 2013; Ishii et al., 2008) 
and/or non-covalent interactions such as hydrogen bonding, π-π interactions or charge-
charge interactions between the side chain residues or backbone of the target protein and an 
inhibitor (Landau et al., 2011; Cheng et al., 2013; Tu et al., 2015; Cao and Raleigh, 2012) 
which may influence one or all stages of the aggregation processes. The Eisenberg group 
revealed at least two various binding modes of amyloid pharmacophores which non-
covalent interactions can be outlined by comparatively “tight” (e.g., co-crystal structure of 
Orange G bound to Aβ fibril fragment KLVFFA) or “less tight” binding (e.g., co-crystal 
structure of curcumin bound to  fibril fragment VQIVYK) inside the cross β spine of 
single crystal structures of amyloid fragment sequences from Aβ and  (Landau et al., 
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2011). Nevertheless, the formation of a common amyloid pharmacophore mediated by 
primarily non-covalent bonding interactions does not explain that in some cases these 
forces, which characterize EGCG mediated anti-amyloid activities in a number of amyloid 
systems, are ineffective in others (Popovych et al., 2012). On this basis, a number of 
articles have shown that covalent adduct formation may happen between the nucleophilic 
side chain thiols, amines (as well as the amino terminal amine) and the electrophilic 
carbonyls inside o-quinone intermediates and/or aldehyde groups (Palhano et al., 2013; 
Ishii et al., 2008). Covalent adduct formation influences the anti-aggregation activities of 
baicalein on α-synuclein materially (Hong et al., 2008; Meng et al., 2009) and probably 
also on amylin. Adduct formation also influences binding affinity of EGCG and 
remodeling of Aβ plus amylin8-24 fibrils (Palhano et al., 2013). This mechanism seems to 
be essential that inhibits phosphatase-cleaved amyloid precursor peptide (PAP)248-286 
amyloid production (Popovych et al., 2012). Similar mechanisms have been suggested for 
noticed inhibitory effects of taxifolin on Aβ aggregation and for oleocanthal and 
cinnamaldehyde on  amyloid formation (Li et al., 2009; George et al., 2013).  
 
1.6.2. Non-covalent and covalent inhibition mechanism 
The specificity and type of the non-covalent interactions that mediate amyloid 
inhibitory activity may depend on the protein or the degree of aggregation that is targeted 
(Ehrnhoefer et al., 2008; Thapa et al., 2016). So, numerous of the non-covalent interactions 
do not imply a comprehensive description of all non-covalent interactions that may mediate 
the amyloidogenic activities of an inhibitor. Rather it is a summary of the key interactions 
that are relevant within the given context of a particular inhibitor. Two widely studied 
compounds, EGCG and curcumin are used, as exemplary non-covalent and covalent 
interactions. 
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Curcumin has been reported to modulate amyloid assembly in different amyloid 
systems. Since curcumin is a potential pan-assay interference compound (Nelson et al., 
2017), it is especially important to conduct several orthogonal studies to validate the 
biological activities of curcumin. Nevertheless, extensive literature indicates that curcumin 
prevents amyloid induced cytotoxicity, amyloid formation, and provides advantageous in 
vivo effects including reduced plaque burden and clearance via to inhibit amyloid 
aggregation in the instances of amylin or Aβ to accelerate α-synuclein aggregation, 
resulting in less harmful intermediates and non-soluble aggregates (Jha et al., 2016). Using 
experimental structural data, computer simulation work has gained insights into key 
noncovalent interactions between curcumin and the general cross  spine structure present 
in fibrillar amyloid structures. 
According to amyloidogenic “steric zipper” hexa-peptide amyloid  fragments and 
full length Aβ1-40 docking simulations, curcumin binds within the inter strand space 
(maintained at typical 10 Å distance of protein fibrils; Figure 11A) in a planar fashion, its 
phenyl heads are parallel to the fibril axis. Subsequent analysis has shown that curcumin 
formed the most important inter-residue side chain interactions that targeted the bolded 
residues inside segment KLVFFA of the octamer hexa-peptide assembly and residues 
HQKLVFFA in amyloid β peptide complete lengthwise (Rao et al., 2015). In both cases, 
interatomic distances inside these residues and specific regions of the curcumin molecule 
indicated a number of important non-covalent relationships that were mediated by 
hydrogen bonding and hydrophobic interactions (Figure 11A). These include interactions 
between His14 (π stacking) as well as aromatic phenyl rings of curcumin and between 
Val18 (π-alkyl stacking) and the phenyl ring of curcumin. 
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Figure 11. Illustrative representations a number of proposed mechanisms between 
inhibitors and amyloid proteins. (A) Mechanisms of non-covalent interaction with 
curcumin. Left panel: The planar molecule of curcumin is depicted by a cartoon schematic 
within the cross- spine of an octomeric fibrillar backbone. (B) Mechanisms of covalent 
interaction. Small molecule naturally occurring compounds that contain electrophilic 
functional groups as an example o-quinones and aldehydes form covalent adducts with 
anti-amyloidogen proteins and prevent amyloid fibril formation (Velander et al., 2017). 
 
Other interactions include hydrogen bond between two separate Lys16 groups (projected 
inward from opposite threads of the cross-β spine) (Rao et al., 2015). As a result of binding 
of curcumin, β-sheet perturbations occur within the cross-β spine that may have 
experimentally important consequences (Jha et al., 2016) relevant to inhibition of fibril 
formation (Ono et al., 2004; Yang et al., 2005; Singh et al., 2013). In fact, a similar 
mechanism of “binding and destabilization” has lately been reported with  hexa-peptide 
VQIVYK that binds of curcumin (Berhanu and Masunov, 2015). Recently, the Eisenberg 
group has solved the structure of the curcumin-bound  hexapeptide crystal, which shows 
that the curcumin is intercalated within the inter-β-sheet pocket of four interacting 
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oligomeric chains, with curcumin oriented in a longitudinally parallel to the fibril axis 
(Landau et al., 2011). In another recent study, MD simulations were used to investigate 
molecular relationships mediating amylin-curcumin interactions. MD simulations have 
supported that multiple curcumin molecules associate primarily themselves, and form a 
nucleation site, characterized by exposed hydrogen bonding and hydrophobic relationships 
that bind to and stabilize small order amylin oligomeric “Nano-assemblies” that alleviate 
the higher order amyloid aggregation (Nedumpully-Govindan et al., 2016). 
The non-covalent interactions observed in these complexes show not only a 
mechanistic approach to the effects of curcumin (Thapa et al., 2016; Jha et al., 2016), with 
its anti-amyloid effects (Yang et al., 2005), the molecular scaffold of the curcumin can of 
targeting the cross beta spine in all fibrillary amyloid structures, as well as α-helical 
oligomers that can play an important role during the early occurrences of amyloid 
aggregation (Knight et al., 2006; Abedini and Raleigh, 2009). 
EGCG exerts strong anti-amyloid effects against many amyloidogenic proteins. It is 
capable of preventing the toxic prefibrillar oligomers’ formation (while stabilize non-toxic 
off pathway oligomers), transform previously existing amyloid fibrils into insoluble less 
toxic aggregates and can inhibit amyloid fibril formation (Bieschke et al., 2010; Engel et 
al., 2012; Lopez del Amo et al., 2012). Several studies have described some of the key 
non-covalent binding interactions and events that mediate these effects. Multiple studies 
show that EGCG exhibits non-specific hydrogen bonding and hydrophobic interactions that 
can mediate its anti-amyloid activities: NMR data as well as nitro blue tetrazolium dye 
staining analysis suggest that EGCG can bind to amyloid β peptide and natively 
unstructured α-synuclein or denatured bovine serum albumin but no any other native 
globular proteins. Based on these data EGCG may tends to target natively unstructured or 
unfolded proteins, presumably via non-especial backbone interactions (Ehrnhoefer et al., 
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2008). EGCG may convert the produced amyloid created using the mutant form of 
acetylated fragment of yeast prion protein Sup35 (GNNQQNFQQF) but not the native 
fragment (GNNQQYQQY). Such differential effects may be due to the mutant fragment 
which contains larger hydrophobic binding regions that may interact with EGCG (Palhano 
et al., 2013). Using a series of amylin mutants, Raleigh’s group examined the importance 
of covalent or residue-specific aromatic/hydrophobic interactions that could affect EGCG-
induced amyloid inhibition and/or transformation. It was concluded that non-of them were 
critical, and that backbone hydrophobic/hydrogen bonding interactions likely convey the 
effects of EGCG (Cao and Raleigh, 2012).  
Other studies have shown that EGCG inhibits amylin amyloid aggregation or 
transformation of preformed amylin8-24 fibrils attenuated in the presence of negatively 
charged lipid bilayers (Palhano et al., 2013; Engel et al., 2012).  Based on these data, key 
non-polar and polar regions of amylin that mediate the hydrogen bonding and non-specific 
hydrophobic interactions, as suggested by Raleigh et al. (Cao and Raleigh, 2012), are 
sequestered by both detergent and lipid bilayers, resulting in less interactions with EGCG. 
The anti-amyloid activities of EGCG can be promoted by the binding protein 
specific regions and/or residue: Data from ion mobility mass spectrometry, biochemical 
assays, computational simulations and 2D NMR spectroscopy suggest that EGCG-Aβ 
binding results in compact dimeric and monomeric conformations, as well as higher order 
SDS-stable Aβ oligomers that are mediated by non-polar and polar interactions between 
EGCG and the hydrophobic aromatic core of Aβ (Hyung et al., 2013). 
In summary, the anti-amyloid activity of EGCG is mediated by a wide spectrum of 
non-covalent interactions whose overall contribution to the observed anti-amyloid activity 
and specificity is determined by the interacting protein: for amylin, non-specific 
interactions (i.e., hydrogen bonding/hydrophobic interactions) are sufficient to promote the 
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activity of anti-amyloid EGCG; this is in contrast sharply with its inhibition of PAP 
amyloid, wherein specific interactions are indispensable. The above discussed dichotomous 
behavior is also a deviation from an inhibitory mechanism which is defined by a common 
phenolic pharmacophore, as described by studies experimenting with curcumin and Orange 
G (Landau et al., 2011). As far as we know, high-resolution structural information is yet to 
be obtained for EGCG in complex with an amyloid peptide.  
From certain flavonoid or catechol-containing phenolic compounds, the presence of 
o-quinone mediated covalent adduct formation with amyloid proteins has been suggested 
or verified by several studies (Palhano et al., 2013; Popovych et al., 2012; Hong et al., 
2008). Further covalent mechanisms have also been reported to occur between nucleophilic 
amines, thiols of amyloidogenic proteins and electrophilic reactive groups on inhibitors 
like aldehydes (Figure 11B, Middle and Lower Panels; (George et al., 2013)). Selected 
cases and major covalent inhibition mechanisms are discussed below. 
In order to present instances for oquinone mediated covalent mechanisms, we will 
use EGCG, taxifolin, baicalein, and catecholamines. Site specific adduct formation to 
lysine residues in (PAP)248-286 is vital for EGCG-mediated anti-amyloid activity as well as 
SDS-stable insoluble aggregate formation of (PAP)248-286. This was confirmed by a series 
of NBT binding assays, transmission electron microscopy and NMR analyses (Hong et al., 
2008). In addition, mass spectrometry implies that gallocatechin (GC), which does not have 
the gallic ester moiety presented in EGCG but possesses the three contiguous hydroxyl 
groups on the B-ring, undergoes less conjugation with (PAP)248-286, neither stabilizing low 
molecular weight SDS-stable PAP oligomers nor inhibiting PAP amyloid formation. This 
indicates that the gallic ester moiety present in EGCG is required for yielding a sufficient 
amount of adduct formation (i.e., 35% in EGCG-PAP samples versus 10% observed in 
GC-PAP samples) needed to confer anti-amyloid activities. These effects may be 
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consequences caused by higher stoichiometric amounts of gallol functional groups capable 
of oquinone formation in EGCG (versus GC). However, the gallo ester may facilitate initial 
noncovalent EGCG-PAP interactions as suggested by NMR experiments, that locates 
EGCG in a more favorable orientation and position (as compared to GC) for covalent 
conjugation, suggest that the gallo ester may make initial noncovalent EGCG-PAP 
interactions easier (Popovych et al., 2012). This explanation is similar to the thought of 
how aromatic/hydrophobic residues within the hydrophobic amyloid core may facilitate 
proper pharmacophore positioning of certain polyphenols along the cross-beta spine of 
amyloid fibrils (Porat et al., 2006). 
Taxifolin does not inhibit monomeric or seeded amyloid beta fibril formation in 
anaerobic conditions, neither if a mild reducing reagent is present. But when it is incubated 
under aerobic conditions, taxifolin attenuates beta sheet rich secondary changes and 
prevents Aβ42 fibril formation, a phenomenon quickened in the presence of an oxidizing 
reagent, sodium periodate. Studies working with mass spectrometry and site directed 
mutagenesis proved that the chemical mechanism responsible for taxifolin mediated anti-
amyloid activity transpires via site specific covalent adduct formation, through Michael 
addition at residues Lys16 and Lys28 (Sato et al., 2013). Additional characterizations with 
catechol-type (myricetin and quercetin) and noncatechol type (morin, kaempferol and 
datiscetin) flavonoid compounds indicated that anti-amyloid activities against Aβ1-42 were 
exhibited by all compounds. The results suggest that myricetin and quercetin control their 
anti-amyloid activities through o quinone-Lys covalent adduct formation similar as 
taxifolin but that such a mechanism may not be generalized to all flavonoid molecules. 
Studying a relevant case, baicalein inhibits α-synuclein amyloid formation. It is 
believed that the primary chemical mechanism responsible for this activity takes place via 
formation of baicalein- α- synuclein covalent adducts. When autoxidized into the quinone 
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form of baicalein versus freshly prepared baicalein, anti-amyloid activities of baicalein 
against α-synuclein aggregation are considerably enhanced, but rather weakened under 
conditions of anaerobic quality (Zhu et al., 2004; Meng et al., 2009). 
The disruption of free radical cycling vital to o-quinone auto-oxidation via 5,5-
dimethyl-1-pyrroline-N-oxide radical quenching reagent reduced anti-amyloid effects of 
baicalein in a significant way (Meng et al., 2009). At last, the fact, that the o-quinone form 
of baicalein forms covalent adducts with α−synuclein, was confirmed by results from mass 
spectrometry (Zhu et al., 2004; Meng et al., 2009). Also, inhibitory effects of baicalein 
against amylin oligomerization, amylin amyloid-induced toxicity and fibril formation have 
been described and validated using varying analytical approaches. Moreover, systematic 
structure activity studies working with a series of baicalein analogues produced definite 
evidence for a key role in catechol moiety in mediating the above discussed effects. 
Importantly, Mass spectrometric evidence showed schiff-base mediated baicalein-amylin 
adducts (Velander et al., 2016). 
 It is worth to consider that this mechanism is explainable by the ability of baicalein 
to undergo auto-oxidation to the o-quinone form and in turn to form covalent adducts with 
amylin. Several quinones and amino chromes derived from oxidized catecholamines 
undergo o-quinone mediated protein covalent adduct formation leading to the dissolution 
of both preformed Aβ and α-synuclein amyloid fibrils, as suggested by numerous studies 
(Conway et al., 2001; Li et al., 2004; Mazzulli et al., 2016). Cinnamomum (tree) verum 
extract has been shown to prevent amyloid fibril formation from tau and hen egg-white 
lysozyme (Ramshini et al., 2015; Peterson et al., 2009). More recently, it has been 
confirmed that cinnamaldehyde, a significant component of cinnamon bark oil, inhibits 
Tau187 amyloid formation without having an effect on tau mediated microtubule assembly 
(George et al., 2013).  
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Titration of lysine into the mixtures having both tau and oleocanthal reduces tau 
amyloid formation, in a lysine concentration dependent way. A reduction like that is 
consistent with the potential of lysine to form adducts with the aldehyde reactive-functional 
groups in oleocanthal (possibly even more readily than tau), resulting in fewer oleocanthal 
molecules available for inhibiting tau amyloid (Li et al., 2009). 
 
1.7. Natural product and dietary supplement based amyloid inhibitors 
Natural compounds are complex chemical multiple-target molecules found most 
commonly in plants and microorganisms. These agents have been extensively studied 
because of their antioxidant and anti-inflammatory qualities. However, additionally to their 
potential to prevent damage caused by oxidative stress, they have been proven to modulate 
multiple signal transduction pathways through direct effects on enzymes like kinases, 
regulatory proteins and receptors (Bagli et al., 2016). Dietary natural products are a rich in 
phytochemicals and active compounds that inspire future drug development for AD (Table 
2.). In the last decade, it was reported that certain fruits, vegetables, spices, drinks and 
beverages have the potential to counteract AD pathogenesis. To illustrate this, some dietary 
habits, like a Mediterranean diet (MeDi) and marine products, have a promising effect for 
attenuating the clinical features of AD patients (Modi et al., 2015; Essa et al., 2012; 
Mosconi et al., 2014; Teixeira et al., 2013). They effectively inhibit oxidative stress, Aβ 
accumulation and toxicity, tau phosphorylation, and neuroinflammation and exhibit 
antioxidant and anti-inflammatory qualities. Also, associations with reductions in other 
pathophysiological conditions of AD while learning ability, improving memory, cognitive 
function and protecting against the death of neuronal cells, were associated with these 
dietary components (Essa et al., 2012; Eskelinen et al., 2009). 
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Nature gifted humanity with a plethora of flora-bearing fruits, vegetables and nuts. 
The wide range of bioactive nutrients present in these natural products is crucial in 
preventing and curing various neurodegenerative diseases, for example AD, multiple 
sclerosis, Parkinson’s disease and other neuronal dysfunctions. Piles of evidence suggest 
that common phyto-compounds, flavonoids like polyphenolic antioxidants found in fruits, 
vegetables, herbs and nuts, may potentially hinder neurodegeneration, and improve 
memory and cognitive function. Nuts such as walnut have also demonstrated 
neuroprotective effect against AD (Essa et al., 2012).  
The molecular mechanisms behind the curative effects mainly rely on the action of 
phytonutrients on distinct signaling pathways, which are associated with 
neuroinflammation and protein folding. The emphasis is put on traditional herbal 
medicines and small molecules (usually plant secondary metabolites) as potential anti-
inflammatory drugs, particularly in respect to cytokine suppression by many studies. To 
illustrate this, ω-3 polyunsaturated fatty acids and a number of polyphenolic 
phytochemicals have been shown to work against inflammation in cell and animal models. 
Some of these plant secondary metabolites have also been shown to have effects of 
antioxidant, anti-inflammatory, anti-amyloidogenic, neuroprotective, and cognition-
enhancing qualities (Apetz et al., 2014). 
Most of the active ingredients of medicines are gained from natural products 
(Vickers and Zollman, 1999). Five FDA-approved drugs agents received by screening 
natural sources like plants, marines and microbes has led to the discovery of numerous 
clinically useful drugs, which are much needed in the treatment of human diseases 
(Brahmachari, 2010). Natural flora and fauna have always been and is an essential medical 
reservoir, with a vast number of modern FDA approved products having been derived from 
them (Harvey, 2008; Newman and Cragg, 2012).  
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Table 2. Potential natural bioactive compounds with protective effect against Aβ 
Alzheimer’s disease. 
 
No. Active 
compounds 
Structures* Sources  Activities 
1 (-)-
Epigallocatechin 
gallate 
 
Green and 
black tea 
Reduces Aβ mediated 
cognitive impairment and 
modulates tau pathology 
(Rezai-Zadeh et al., 
2008; Sgarbossa and 
Antonella, 2012). 
2 Apigenin 
 
Parsley, celery, 
cloves, spinach 
and red wine 
Relieves Aβ burden, 
suppresses the 
amyloidogenic process, 
inhibits oxidative stress 
and restores 
ERK/CREB/BDNF 
pathway (Zhao et al., 
2013). 
3 Baicalein  
 
 
Scutellaria 
baicalensis 
(Root) 
 
Reduces Aβ production 
and improves cognitive 
performance (Zhang et 
al., 2013). 
4 
 
Berberine 
 
 
European 
barberry, 
goldthread and 
Oregon grape 
Ameliorates Aβ 
pathology, gliosis and 
cognitive impairment 
(Durairajan et al., 2012). 
5 Caffeine  
 
Coffee Restores memory and 
decreases brain Aβ levels 
(Arendash et al., 2009). 
6 Catechin  
 
Cocoa  Inhibits Aβ-induced 
apoptosis (Heo and Lee, 
2005). 
7 Curcumin  
 
 
Turmeric 
 
Reduces amyloid 
aggregation via metal 
chelation, which may 
reduce amyloid 
aggregation or oxidative 
neurotoxicity in AD 
(Baum and Ng, 2004). 
8 Hydroxycinnamic 
acids 
 
Virgin olive oil Exerts neuroprotective 
effects against Aβ-
induced cytotoxicity  
and oxidative stress 
(Villareal et al., 2016). 
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9 Luteolin 
 
 
Parsley, celery, 
peppers, olive 
oil, lemons, 
peppermint and 
sage 
Downregulates the 
expression of APP and 
reduces the secretion of 
Aβ (Liu et al., 2011). 
10 Nobiletin 
 
Peels of citrus 
fruits like 
tangerine 
and orange 
Decreases Aβ burden and 
improves memory 
impairment (Onozuka et 
al., 2008). 
11 Oleuropein  
 
Olive  Inhibits Tau aggregation 
(Daccache et al., 2011). 
12 Piperine  
 
 
Black pepper 
and long 
pepper 
 
Decrease lipid 
peroxidation and 
acetylcholineesterase 
enzyme 
(Chonpathompikunlert et 
al., 2010). 
13 Quercetin 
  
Apples, 
berries, black 
and green tea 
and red wine 
Inhibits the formation 
and aggregation of Aβ 
(Ansari et al., 2009). 
14 Resveratrol 
 
Majorly found 
in grapes and 
red wine 
Helps in clearance of Aβ 
peptide (Marambaud et 
al., 2005). 
15 Rosmarinic acid  
 
Basil, lemon 
balm, 
rosemary, sage, 
thyme and 
peppermint  
Inhibits β sheet in tau 
protein and β-secretase 
activity, decrease 
mitochondrial 
dysfunction (Cornejo et 
al., 2017). 
16 Xanthone  
 
 
Purple 
mangosteen 
 
Protects against Aβ- 
induced cytotoxicity and 
oxidative stress 
(Moongkarndi et al., 
2010). 
17 Yessotoxin 
 
 
Marine 
dinoflagellate 
(Lingulodinium 
polyedrum) 
 
Inhibits tau 
hyperphosphorylation 
and Aβ accumulation 
(Alonso et al., 2013). 
 
*The structures were re-generated from http://molview.org/. Here, the different colors 
represent various atoms in the molecules, where grey=carbon, white=hydrogen, 
red=oxygen, blue=nitrogen and yellow=sulfur. 
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In the field of Alzheimer’s, the experimental outcomes have already confirmed a 
number of conclusions on the possibility of natural product leads; the majority of the 
compounds examined to date in direct connection with AD primarily come from one 
source; plants which have comparatively few molecules. These molecules are derived from 
marine and microbial sources. The greatest successes, which have developed two of the 
five currently approved drugs for the treatment of AD, have been the results of plant-based 
AChE discovery programs (Houghton and Howes, 2005). 
Multiple factors may be the driving force of the increased interest in natural 
supplementation and for its use in Alzheimer’s and other neurodegenerative diseases; it is 
obvious that the lack of a safe, effective, proven therapy is a contributing factor regarding 
the search for alternatives. There is a wide range of raw plant extracts/ herbal formulations, 
which have a great use as natural remedies in the treatment of AD and other 
neurodegenerative diseases (Houghton and Howes, 2005; Howes and Houghton, 2003; 
Howes et al., 2003). 
Traditional natural medical systems such as Indian, Chinese, Native American, and 
medieval European have offered various “brain tonics” and memory enhancers. Including 
“Ashwagandha” (Withania somnifera; Solanaceae) and Brahmi (Bacopa monnieri L. 
Pennell; Scophulariaceae) described in Indian Ayurveda as memory enhancers, the 
common ‘Sage’ plants (Salvia species; Labiatae) is said to be “good for the memory” in 
Roman texts, and Gingko biloba (Ginkgoaceae) is studied in Chinese literature as a 
possible herb for memory loss as early as 2800 BC. Indian turmeric (Curcuma longa; 
Zingiberaceae) contains an antiinflammatory compound and antioxidant called curcumin, 
which is found to be most effective in the treatment of AD. Vegetables like pumpkins, 
carrots, spices like zinger, sesame and sunflower seeds containing various chemical agents 
are quite nurturing for the function of the brain. More recently, consumption of 
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blueberries/grapes and pomegranate juice has been confirmed to beneficially effect the 
state of AD patients. In addition, food supplements of vitamin B6, B12, E, and C, folic acid 
and co-enzyme Q10 have been found to have positive effect in AD patients (Tildesley et 
al., 2003; Scholey et al., 2008; Wang et al., 2008). 
Natural phenolic compounds, being a long family of plant substances, are one of the 
most actively researched categories of potential amyloid inhibitors (Stefani and Rigacci, 
2013; Shariatizi et al., 2015; Jayamani and Shanmugam, 2014). Currently, more than 8,000 
plant polyphenols are discovered including more than 4,000 flavonoids identified (Pandey 
and Rizvi, 2009). Resveratrol inhibits Aβ42 fibril formation and islet amyloid polypeptide 
aggregation dose-dependently (Feng et al., 2009; Evers et al., 2009). This inhibitory effect 
of flavone derivatives dependents on the position and number of hydroxyl groups around 
the flavone backbone (Šneideris et al., 2015). The position of phenolic hydroxyl moieties 
on the aromatic rings is a strong determinant of the potent anti-aggregation effect. In 
contrast, the number of hydroxyl groups is less important (Porat et al., 2006). 
Natural phenolic and polyphenolic substances are to stabilize native states, or to 
remodel and to inactivate toxic amyloid oligomers (Stefani and Rigacci, 2013). A number 
of observations implies that polyphenols prevent amyloid fibril formation via specific 
aromatic interactions with the amyloidogenic core (Porat et al., 2006). It may be that 
aromatic rings of polyphenolic compounds and the aromatic residues found in proteins 
associate via π-π stacking interactions (Bhat et al., 2015). The hydrophobic and/or aromatic 
character of these compounds is a contributing factor to the antiamyloidogenic effect, 
whereas the antioxidative potency is mostly related to the destabilization of fibrils (Shoval 
et al., 2007). According to studies, the presence of vicinal dihydroxyphenyl moieties, 
irrespective of their position in the aromatic rings, is vital regarding the inhibitory property 
of polyphenols (Bhattacharya et al., 2014; Ghosh et al., 2013). Non-flavonoids exhibited 
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higher anti-aggregation activity compared to flavonoids. Polyphenols contain more of 
aromatic rings, hydroxyl and keto groups, and have a high degree of planarity, exhibit the 
largest inhibitory activity (Lakey-Beitia et al., 2015). According to a study on structure–
function relationship, the presence of minimum two phenolic rings with two to six atom 
long linkers, along with at least three hydroxyl groups on the aromatic rings, are crucial for 
efficient inhibition exerted by polyphenols (Shariatizi et al., 2015). The mechanism of 
inhibition of amyloid formation is not the same each natural polyphenol. Some of them 
inhibit the formation of oligomers, but promote fibril formation, others are known to inhibit 
the formation of fibrils, but not oligomers, and there are even those inhibiting both. A 
different group of polyphenols redirect amyloid fibrils from fibrillogenic forms to 
nonfibrillogenic oligomers. Conformational changes are induced in the oligomer aggregate 
by polyphenols. H-bonds are disrupted by these changes, and the amyloid aggregate is 
perturbed. The β-sheets are separated by polyphenol molecules, resulting in a loosely 
packed structure. H-bonding capacity of polyphenols is the cause of this behavior 
(Ngoungoure et al., 2015). Flavonoids, especially phenols, are essential components of a 
normal human diet. Correlation between an elevated intake of dietary polyphenols and the 
prevention of amyloidosis is to be considered. It is possible, that nutraceutical strategies 
become a way to increase the chances of preventing certain amyloid diseases. For many of 
the drugs being used today are natural products or derivatives of natural products (Berhanu 
et al., 2015; Yamada et al., 2015). 
 
1.7.1. Medicinal herbs & spice extracts 
 
In spite of the fact that we, humans, have been using a quite wide range of spices 
for more than 2000 years, the research of their biological activities has just recently begun 
(Mirmosayyeb et al., 2017). Nuts, fruits, spices and herbs also possess important bioactive 
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compounds – without unwanted side effects – needed for the prevention and cure of many 
diseases (Iriti et al., 2010; Essa et al., 2012). Extracts from kitchen spices are known to 
contain therapeutic natural compounds considered to be highly promising. The main 
components of spice extracts contain biologically active flavonoids, di- and triterpenoids, 
phytosterols, tocopherols, phytosterols, alkaloids, phenolic acids, carotenoids, vitamins and 
other compounds (Misharina, 2016). Molecules known to inhibit protein misfolding have a 
great promise regarding therapeutics for the treatment of diseases, which are caused by the 
formation of amyloid fibrils (Barbero et al., 2014). 
Cayenne pepper (Capsicum annuum L) contains the five major capsaicinoids: 
nordihydrocapsaicin, capsaicin, homocapsaicin, dihydrocapsaicin, and 
homodihydrocapsaicin. Two major capsaicinoids are capsaicin and dihydrocapsaicin, 
representing between 79% and 90% of total capsaicinoids, respectively, also depending on 
fruit ripening (Barbero et al., 2014). Cayenne pepper contains more capsaicin than 
dihydrocapsaicin (Bajer et al., 2015). Carotenoids are the second group of main 
components of pod. In pepper, thirty-four carotenoids were discovered and identified. Four 
main carotenoids are responsible for the red color of pepper. (capsorubin, capsanthin, 
cryptoxanthin, zeaxanthin). Among these four, capsanthin is found to be the main and the 
most stable compound, and accounts for up to 60% of all the carotenoids. In fresh rods, 
carotenoids are stable, but exposed to autoxidation in milled or dried ones. Although pod 
pepper has vitamins, flavonoids and about 50 volatile compounds causing the flavor, their 
total content is insignificant, they only sum up to less than 0.01% (Misharina, 2016). The 
more peppers grew and the concentration of carotenoids and capsaicinoids got higher, the 
less they contained phenols and flavonoids (Tundis et al., 2013; Menichini et al., 2009).  
Saffron (Crocus sativus) is contained of polar carotenoids. Its main secondary 
metabolites are safranal responsible for odour, crocin for colour and picocrocin for taste. 
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Experimental results show that Crocus sativus stigma extract shows inhibitory action on 
fibrillogenesis and Aβ aggregation. The main carotenoid trans-crocin 4, the digentibiosyl 
ester of crocetin is held responsible for the anti-amyloidogenic activity. It is possible that 
the molecular mechanism inhibiting fibril formation is due to the capability of crocin to 
bind to the hydrophobic regions of Aβ (Essa et al., 2012; Papandreou et al., 2006). The 
anti-amyloidogenic effect of crocin is exerted by the inhibition of Aβ amyloid formation, 
but the disruption of amyloid aggregates also exerts it. So, crocin may prove to be 
important, while searching for therapies inhibiting or disrupting aggregation (Ghahghaei et 
al., 2013). 
Oligomerization of Aβ, human islet amyloidogenic polypeptide promoting fibril 
deposition, and hen egg white lysozyme is inhibited by curcumin derived from turmeric, 
while it also inhibits both the fibrillation and the oligomerization of PrP (Stefani and 
Rigacci, 2014; Pithadia et al., 2016). Curcumin alters the aggregation of proteins, reduces 
the toxicity of the aggregates (Ahmad et al., 2017) and inhibits alpha-synuclein 
oligomerization into higher molecular weight aggregates (Pandey et al., 2008). Basil is rich 
in phenolic acids contributing to a potent antioxidant capacity. Substantial concentrations 
of rosmarinic acid have been associated with the medicinal qualities of the herb. In the 
literature rosmarinic acid is described to be the most prevalent basil phenolic, however, 
high concentrations of other caffeic acid derivatives, for example chicoric acid, are also 
found (Kwee and Niemeyer, 2011). Hen egg white lysozyme amyloid aggregate formation 
was effectively inhibited by rosmarinic acid (Ramazzotti et al., 2016). The aqueous extract 
of clove has a significant amount of polyphenols (Suantawee et al., 2014). Cinnamon is a 
great source of proanthocyanidins, for instance, a group of plant polyphenols (Williams et 
al., 2015). Fifty-two phenolic compounds were discovered in culinary herbs (rosemary, 
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thyme, bay and oregano) and spices (cumin and cinnamon) (Vallverdú-Queralt et al., 
2014).   
Spices are proven to be great polyphenol sources. Their high polyphenolic content 
was found to be related to numerous health benefits (Hossain et al., 2011). It is possible 
that the aromatic rings of polyphenol interact with aromatic residues in amyloidogenic 
proteins competitively, block the self-assembly process and inhibit the π-π interaction. 
Amyloid fibril formation may be inhibited by the phenolic hydroxyls of polyphenols, 
through binding the hydrophobic residues in amyloidogenic proteins (Cheng et al., 2013). 
The key determinant for the anti-amyloidogenic properties was found not to be the number, 
but to be the position of hydroxyl groups on the aromatic ring (Porzoor et al., 2015). 
According to reports, many herbs contain flavonoids and other phenolic antioxidant. Good 
examples are basil, chives, coriander, dill, lovage, mint, oregano, parsley, rosemary, and 
safflower, sage, tarragon and thyme (Justesen and Knuthsen, 2001; Yu et al., 2013). 
Pinocembrin, identified in a number of plants, for example ginger roots and wild marjoram, 
is a natural flavonoid compound (Lan et al., 2016). Pinocembrin is potentially a promising 
substance for the prevention and therapy of Alzheimer's disease (Liu et al., 2012). 
According to the results, a constituent of ginger named 6-shogaol inspires much hope as a 
therapeutic agent for the treatment of various neurodegenerative diseases, including 
Alzheimer’s disease (Na et al., 2016). 
The anti-amyloid activities of 27 vegetables, spices and herbs were screened by 
Ana Lucia Fuentes and her co-workers. It was found that mint, peppermint, red bell pepper 
and thyme had the greatest anti-amyloid activity (Fuentes et al., 2016). 
Peppermint can prove to be an important source of biologically active compounds 
(Alexa et al., 2018). It is possible that flavones (e.g. luteolin derivatives), flavanones (e.g. 
eriocitrin derivatives and phenolic acids (e.g. caffeic and rosmarinic acids) are the main 
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infusion antioxidants. Catechin, (-)-epigallocatechin gallate, syringic, vanillic, gallic and p-
coumaric acids were also identified in it. Peppermint is effective at inhibiting the 
aggregation of islet amyloid polypeptide (Uribe et al., 2016). The molecular mechanism, 
by which EGCG inhibits human islet amyloid polypeptide aggregation, was researched. 
According to this research, EGCG binding inhibits the aromatic-stacking and inter-peptide 
hydrophobic interactions responsible for intra-peptide interaction and inter-peptide β-sheet 
formation. For β-hairpin formation, the last two phenomena are essential.  
EGCG binding thus does away with the three-stranded β-sheet structures and leads 
to the formation of coil-rich three-dimensional structures. The effect of a simple 
polyphenol called gallic acid (GA) was observed. GA is one of the most significant 
components in plant tissues, above all in tea leaves. GA inhibits the conformational 
transition of α-helix → β-sheet usually induced during insulin fibril formation. GA is 
known to interact with native insulin, inhibiting nuclei formation, which is required for 
fibril growth, thereby preventing amyloid fibril formation (Jayamani et al., 2014). Not only 
did GA prevent alpha-synuclein fibrillation and toxicity but also disaggregated preformed 
alpha-synuclein amyloid fibrils. Surprisingly, GA bound to soluble, non-toxic oligomers 
with no β-sheet content, and stabilized their structure (Ardah et al., 2014). An extract of 
Salvia officinalis (garden sage) was supplied with, polyphenolic compounds containing 
rosmarinic acid (Bakota et al., 2015).  
In a research studying cultivated and wild nettle leave samples caffeic acid 
derivative, 2-O-caffeoylmalic acid, chlorogenic acid, kaempferol 3-O-rutinoside, rutin, 
quercetin 3-O-glucoside and isorhamnetin 3-O-rutinoside were detected by phenolic profile 
and HPLC analysis. Caffeic acid derivative, p-coumaric acid, chlorogenic acid, rutin, 
quercetin 3-O-glucoside, 2-O-caffeoylmalic acid, kaempferol 3-O-rutinoside, isorhamnetin 
3-O-rutinoside were discovered in wild leaf samples (Otles et al., 2012). Melilotus 
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officinalis contains coumarin and related compounds like o-coumaric and melilotic acids, 
flavones, volatile oils, tannins and resins (Martino et al., 2006). Analogs of common 
coumarin were identified as a new kind of inhibitors of Aβ aggregation (Soto-Ortega et al., 
2011). 
 
1.7.2. Chinese dietary supplements  
 
The traditionally used herbal medicine Panax ginseng Meyer shows hypolipidemic 
and hypoglycemic effects (Jeon et al., 2013; Trinh et al., 2007; Park et al., 2011). It also 
exhibits beneficial effects on cancer patients (Park et al., 2011) and inflammations (Yuan 
and Chung, 2010; Seo et al., 2005). In addition, it has also been confirmed to have 
therapeutic effects on allergic rhinitis in clinical patients (Jung etal., 2011). Moreover, 
neuro- (Chen et al., 2012) and cardioprotective (Peng et al., 2012) effects of P. ginseng 
were also discussed. Ginsenosides, being the main molecular components found in 
ginseng, have also been effectively implemented in the treatment of cognitive impairments 
(Zhao et al., 2009), for example the amelioration of Aβ plaques (Tohda et al., 2004). The 
fibril formation of reduced and carboxymethylated κ-casein was dose-dependently 
inhibited by the ginsenoside Rg1 and Rb1 (Chen et al., 2016). However, it appears that 
other different components of P. ginseng have also been described as biologically active, 
for example polysaccharides, peptides, fatty acids and polyacetylenic alcohols (Attele et 
al., 1999; Kim et al., 2013).  
The compounds, that inhibit the formation of amyloid fibril, exhibit 
neuroprotective, anti-aging and antitumor activity, so it is possible that the molecular 
components of ginseng have similar effects. It is also possible for ginseng to act as a tool to 
investigate the amyloid aggregation pathway, and its active components may be used as 
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molecular scaffolds for the development of biologically available and more active drugs 
(Stefani and Rigacci, 2013). 
Terpene trilactones and flavonoid glycosides are the two main groups of 
constituents in the standard extract of Ginkgo biloba leaves. Seven flavonoid glycosides 
were found to exert moderate to weak inhibitory activity on Aβ42 fibril formation whereas 
four terpene trilactones had insignificant effect. Considering this, there must be other 
additional compounds in the extract of Ginkgo biloba leaves, responsible for its inhibitory 
effect on Aβ42 fibril formation (Xie et al., 2014). Catechins and procyanidins, for example 
gallocatechin, (-)- epigallocatechin, (+)-catechin, (-)-epicatechin, (-)- procyanidins B-1 and 
B-3 are present in the extracts of its leaves. These polyphenols inhibit Aβ42 aggregation, 
destabilize preformed fibrils and have been evaluated (Xie et al., 2014).  
 
1.7.3. Commercially available coffees and teas 
 
Coffee is a beverage rich in antioxidant and widely consumed worldwide 
(Pourshahidi et al., 2016; Essa et al., 2012). Coffee consumption has preventive benefits 
with many positive health effects. Its inverse correlation with the occurrence of diabetes 
mellitus, various cancer types, Parkinson’s, and Alzheimer’s disease were confirmed by 
excessive research, epidemiological studies, and meta-analyses concerning coffee 
consumption. These health benefits are due to coffee polyphenols (Ochiai et al., 2014; Butt 
and Sultan, 2011). The chemical structure of polyphenols contains two or more phenol 
rings with hydroxyl groups in ortho or para positions (Lakey-Beitia et al., 2015). It has 
been reported that numerous natural polyphenols have potent inhibitory effects on amyloid 
fibril formation (Lakey-Beitia et al., 2015; Bhattacharya et al., 2014). 
Coffee extracts possess three main active components, i.e. caffeic acid, caffeine and 
chlorogenic acid (CGA). All components show different inhibitory effects on the formation 
of toxic human islet amyloid polypeptide (hIAPP) amyloids, as suggested by earlier 
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findings. CA exhibits the most potency in delaying the conformational transition of the 
hIAPP molecule with the most prolonged lag time, whereas caffeine shows the lowest 
potency (Cheng et al., 2011). It is a proven fact that α-synuclein fibrillization is 90% 
inhibited by CA at 1:1 ratio (Gazova et al., 2013). CA was reported to inhibit Aβ1-42 self-
induced aggregation (Wei et al., 2016). CA can pass through the blood-brain barrier; 
therefore, it has been suggested as an anti-amyloidogenic agent (Fazili and Naeem, 2015).  
Alkaloids are a group of natural organic nitrogen-containing compounds, which are 
primarily present in plants, especially in particular families of flowering plants. Caffeine is 
to be found in many dietary sources such as coffee (71–220 mg caffeine/150 ml), tea (32–
42 mg/150 ml), cola (32–70 mg/330 ml) and cocoa (4 mg/150 ml). Caffeine reduce levels 
of Aβ and Aβ-induced neurotoxicity both in vitro and in vivo (Ng et al., 2015), therefore 
caffeine may prevent Alzheimer’s disease. Caffeine is capable of inhibiting the formation 
of β-sheets by interacting with the peptide’s aromatic side chains of the constituent amino 
acids. Furthermore, caffeine molecules form hydrogen bonds with peptide backbone, 
thereby weaken interstrand hydrogen bonds of β-sheets (Sharma et al., 2016). The 
disruption of the blood-brain barrier occurs at an early pathological stage in Alzheimer’s 
disease. It may make it possible for Aβ to accumulate in the brain. If that is the case, it does 
that by allowing the transport of Aβ produced in the periphery.  
The brain may be protected against Alzheimer’s disease-associated blood-brain 
barrier disruptions by caffeine administration (Madeira et al., 2017). Moreover, trigonelline 
is a coffee ingredient too, and it is one of the most often consumed alkaloids. Molecular 
modelling demonstrated that trigonelline has high affinity to the A-β (1-42) peptide, and 
acts similar to the anti-Alzheimer’s disease drug candidate – cotinine (Makowska et al., 
2014). The neuroprotective activities of CGA against Aβ-caused toxicity were studied, too 
(Lee et al., 2011). Moderate (three to five cups a day) coffee intake in people is associated 
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with a considerable decrease in the risk of developing different chronic diseases (Shukitt-
Hale et al., 2013). According to a recent epidemiological study, higher caffeine 
consumption over decades decreases the risk of having Alzheimer's disease (Arendash and 
Cao, 2010). 
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2. Main objectives and organization of the thesis 
 
One out of eight people aged 65 or older has AD (Citron, 2010). With the 
increasing longevity of our population, AD is approaching epidemic proportions without 
cure or preventative therapy in sight. A pathological hallmark of AD is the extracellular 
deposition of amyloid in the brain. These fibrillar deposits (plaques) are formed from the 
self-aggregation of the β-amyloid (Aβ) peptide, a 38 to 42 residue protein that is normally 
produced as part of the cellular metabolism. Similarly, amyloid composed of other peptides 
or proteins are also found in other neurodegenerative diseases such as Parkinson’s, 
Huntington’s, and prion-related diseases. 
One therapeutic approach is the screening or development of natural bioactive 
molecule inhibitors of Aβ aggregation. Dietary natural products can serve as a rich source 
of phytochemicals and active compounds, having the potential for future drug development 
for AD. In the last decade, researchers reported that certain fruits, spices, vegetables, drinks 
and beverages could have the potential to counteract AD pathogenesis. These natural 
products effectively prevent oxidative stress, Aβ accumulation and toxicity, tau 
phosphorylation, neuro-inflammation and shows antioxidant and anti-inflammatory 
properties. Associations with reductions in other pathophysiological conditions of AD 
while improving memory, learning ability, cognitive function and protecting against 
neuronal cell death were also mentioned regarding these dietary components (Essa et al., 
2012). At present, researchers are searching for new, safer and more effective therapies that 
are capable of more precisely targeting the pathophysiology of AD and inhibiting the A 
accumulation and toxicity.  
Our research group has been working on enzymatic modification of -
chymotrypsin and trypsin on the formation of amyloid-like fibrils in different aqueous 
organic solvents. We have been also investigating the inhibitory activity of various 
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bioactive compounds, the effect of dietary supplements, sorts of red wine, fruits and 
vegetables, coffee, spices, herbs, grapefruit seed extract and peppermint extracts on the 
formation of amyloid-like fibrils of -chymotrypsin and trypsin in different aqueous 
organic solvents. 
Our primary interest here was the discovery of novel molecules possessing anti-
neurodegenerative and anti-amyloidogenic properties through screening of a diverse library 
of natural compounds. By considering these main objectives, our aims were: 
 Collection, extractions of bioactive compounds and total phenolic analysis from 5 
categories or groups of natural products. 
 Modification and examination of trypsin with phenylmethylsulfonyl fluoride 
(PMSF) for the formation of amyloid-like fibril in aqueous organic solvents and 
analysis of inhibitory effect of extracted compounds. 
 in vitro screening by turbidity, size exclusion chromatography, aggregation 
kinetics, CR binding, FTIR, CD and TEM on amyloid-like fibril formation of 
trypsin by coffees, spices, medicinal herbs, Chinese dietary supplements, grapefruit 
seed extract and peppermint extracts in aqueous organic ethanol. 
 Investigation of inhibitors or suitable therapeutic agents for amyloid related 
neurodegenerative diseases.  
 In each of my studies, I have comparatively investigated 5 categories or groups of 
natural product extracts for screening of anti-amyloidogenic properties on the formation of 
amyloid-like fibrils of trypsin in different aqueous organic solvents. 
From these studies, we aim to provide the anti-amyloidogenic and anti-
neurodegenerative natural bioactive extracts from diverse library. 
During the last three decades, tremendous progress was made in the understanding 
of the mechanism of AD. However, discovery or screening of new pharmacological 
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approaches, especially of disease-modifying drugs, has not been successful to date. 
Aggregation of β-amyloid peptides in brain tissue is the likely cause of AD, which means 
that the alpha helical structural changes to the beta sheet are to be considered of 
physiological importance, and they lead to the formation of amyloid structures (Ardito et 
al., 2017). Recent studies on Aβ amyloid formation indicate that several natural small 
aromatic compounds and flavonoids interfere with aggregation pathways possibly by 
remodelling the amyloid intermediates through the different mechanisms or interactions 
(Petkova et al., 2006). 
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3. Materials and methods 
3.1. Materials 
Bovine pancreas trypsin (EC 3.4.21.4; from bovine pancreas), gallic acid, limonin 
(from citrus seeds) and N-benzoyl-L-arginine ethyl ester (BAEE) were purchased from 
Sigma-Aldrich (Budapest, Hungary). Folin-Ciocalteu’s phenol reagent was the product of 
Merck (Darmstadt, Germany). Ginseng Royal Jelly ampoule P. ginseng extract and Royal 
Jelly content vial with honey food supplement was distributed by Oriental Herbs Kft., 
Budapest, Hungary. A total of 31 dried culinary spices were purchased from the local 
supermarket. Chili, rosemary, dill, clove, lovage, tarragon, parsley, thyme, sage, bear’s 
onion and saffron distributed by Kotányi Hungária Kft., Budapest, Hungary, basil, allspice, 
turmeric, caraway seed, safflower, bay leaf and cinnamon imported by R COOP3 Kft., 
Szeged-Szőreg, Hungary, golden cress, coriander seed, oregano, marjoram, cumin, pepper, 
mace, anise, ginger and juniper berry packed by Szilasfood Kft., Kistarcsa, Hungary, 
hibiscus, celery and peppermint were used disassembled by Toldi Fűszer és Delicates Bt., 
Budapest, Hungary. Folin-Ciocalteu’s phenol reagent was the product of Merck 
(Darmstadt, Germany). The different ground, roasted coffees were obtained from 
commercial sources. Eduscho Wiener Extra was purchased from Tchibo Budapest Kft., 
Budaörs, Hungary, Douwe Egberts Omnia Classic from Douwe Egberts Hungary, 
Budapest, Hungary, Bravos Classic from Mocca Negra Zrt., Szentendre, Hungary, Brasil 
Santos, Panama arabica and Kenya Kiandi from Latin Negyed Kft., Szeged, Hungary. 
Grapefruit seed drops with ginseng was purchased from Oriental Herbs Kft., Budapest, 
Hungary. Acai oral liquid was distributed by Big Star Street Kft., Budapest Hungary. 
Grapefruit seed extract was distributed by Bioextra Zrt., Hatvan, Hungary. Virgin Tea 
Ampoule was distributed by Oriental Herbs Kft., Budapest, Hungary. The different herbs 
(peppermint leaves (Menthae piperitae folium), medical sage leaves (Salviae folium), 
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marigold (Calendulae flos), walnut leaves (Juglandis folium), thornapple buds (Crataegi 
folium cum flore), yarrow (Millefolii herba), field horse tail (Equiseti herba)) were 
purchased from Mecsek-Drog Kft., Pécsvárad, Hungary. All other reagents and buffer 
components used were of analytical grade. 
 
3.2. Preparation of water-soluble extracts 
15 ml of distilled boiling water was added to 200 mg of tea. 3 g coffee was added to 
22.5 ml hot (100 
o
C) distilled water, then it was boiled three times. 600 mg of spice was 
added to 6 ml distilled water, then it was brought to boil. After the samples cooled down to 
room temperature, they were being centrifuged for 1 min at 13,000 rpm. The supernatants 
were stored in the freezer until use. The extracts were diluted in distilled water prior to use 
as required. 
 
3.3. General methods 
Trypsin concentration was determined based on the UV absorbance of the 
constituent aromatic and cystine residues at 280 nm, using a calibration curve measured for 
trypsin in the 0-1 mg/ml concentration range. Spectroscopic samples have been corrected 
for appropriate solvent backgrounds in all experiments where applicable. 
 
3.4. Assay of enzyme activity 
The activity of trypsin, with BAEE as a substrate, was determined following the 
method of Schwert and Takenaka (Schwert and Takenaka, 1955). The increase in 
absorption at 253 nm was followed in a 3 ml reaction mixture, which contained 46.7 mM 
Tris/HCl buffer and 0.9 mM BAEE at pH 8.0. The reaction was initiated by the addition of 
20 l enzyme solution at a concentration of 0.15 mg/ml. 
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3.5. Modification of trypsin with phenylmethylsulfonyl fluoride (PMSF) 
Chemical modification of the serine residue at the active site of trypsin with PMSF 
irreversibly inactivates the enzyme. This is required to suppress the autolysis at pH = 7.0, 
which could lead to artefacts in the observation of amyloid formation. 8.4 l 100 mM 
PMSF in 2-propanol and 20 l 50 mg/ml trypsin in 0.001 N HCl were added to 2 ml 0.05 
M potassium phosphate buffer at pH = 7.0 at 24 
o
C while stirring. Such aliquots were 
added to the solution on four occasions. The reaction mixture was left to be stirred for 30 
minutes, then it was fractionated by filtration on a Sephadex G-25 column, with 0.05 M 
potassium phosphate buffer at pH = 7.0 as eluent, to remove excess reagents. The degree of 
modification was calculated from enzymatic activity assays. It was determined that 95% of 
the trypsin had been modified. 
 
3.6. Turbidity measurements 
Turbidity assay was performed as an indicator to suggest the formation of protein 
aggregates and fibrils (Bhat and Bano, 2014; Fazili and Naeem, 2015). Turbidity was 
monitored using a Cecil CE 5501 spectrophotometer. The absorbance of the samples was 
measured at 350 nm wavelength at 24 
o
C in a 10 mm path length cell in the presence or 
absence of different inhibitory agents in 60% ethanol/10 mM phosphate buffer at pH 7.0 
after 24 h incubation, to estimate the rate of aggregation. The concentration of PMS-trypsin 
was 0.13 mg/ml in the turbidity measurements. Respective blank corrections were done in 
the case of each experiment. Inhibition percentages were calculated from the turbidity 
measurements. We subtracted the relative absorption for the given sample from 1, and then 
we multiplied it by 100. Data represent the turbidity measurements of at least three 
independent experiments. All data were presented as mean ± standard error of the mean 
(SEM). 
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3.7. Determination of total phenolic content 
Spectrophotometric analysis of the total phenolic content of samples by means of 
Folin Ciocalteu colorimetric method was performed following the protocol of Waterhouse 
(Waterhouse, 2002). The reaction mixtures were kept for 2 h at room temperature, and 
absorptions were measured at 765 nm using a UV-Vis Cecil CE 5501 spectrophotometer. 
The same procedure was repeated for different concentrations of gallic acid solutions (0–
50 mg/l) as standard, and the calibration curve was plotted. The total phenolic contents 
were expressed as mg gallic acid equivalents per litre (GAE/l) of samples. The data 
presented are the average of three independent measurements. 
 
3.8. Determination of limonin concentration using HPLC-MS 
Liquid chromatographic separation was performed on a DionexUltimate 3000 
UHPLC system equipped with a membrane degasser, a binary pump, a standard 
autosampler, a thermostated column compartment and a variable wavelength detector. The 
components of the sample were separated on a Gemini-NX C18 (3 μm, 150 x 2 mm) 
column (Phenomenex) equipped with a Gemini-NX C18 guard column (5 µm, 4 x 2 mm) 
thermostated at 25 °C. Mobile phase A consisted of water containing 0.1% formic acid, 
while methanol containing 0.1 % formic acid served as mobile phase B. The gradient 
elution was performed as follows: 0 min, 20% B; 1 min, 20% B; 12 min, 95% B; 17 min, 
95% B; 18 min, 20% B; 25.0 min, 20% B. The flow rate was set to 0.2 ml/min. The 
injection volume was 5 µl. 
Mass analyses were performed on a Q Exactive Plus hybrid quadrupole-Orbitrap mass 
spectrometer. Ionization of analytes was performed using heated electrospray interface 
(HESI) in negative electrospray ionization. The temperature of ion transfer capillary, spray 
voltage, sheath gas flow rate, auxiliary gas flow rate were set to 350 °C, 3.5 kV, 35 and 10, 
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respectively. Detection of limonin was achieved in PRM mode monitoring the 
characteristic fragment ion (m/z 469.2>249.1) of the deprotonated molecule. The acquired 
data were processed using Xcalibur™ version 2.2.1 and Trace Finder version 3.3 (Thermo 
Fisher Scientific). 
 
3.9. Aggregation kinetics 
The time dependence of the aggregation of PMS-trypsin in 60% ethanol was being 
monitored on a Hitachi U-2000 spectrophotometer for 30 minutes by monitoring the 
increase of absorption at 350 nm at pH 7.0 and 24 
o
C, in the absence or presence of 
different inhibitory agent concentrations. The increase of UV absorption at 350 nm is 
indicative of the presence of large aggregated particles. The enzyme concentration in the 
aggregation kinetics assays was 0.13 mg/ml.  
 
3.10. Congo red binding 
Absorption spectra of CR (disodium-3,3'[[1,1-biphenyl]-4,4'-diylbis(azo)]bis(4-
aminonaphthalin-1-sulphonate)) were recorded between 400 and 600 nm in a 10 mm-path-
length quartz cell. The concentration of CR solution was determined using ɛM: 
45,000 M
−1
 cm
−1
 at 498 nm (Klunk et al., 1989; Chaturvedi et al., 2015). Aliquots were 
prepared with protein concentration of 0.13 mg/ml in 60% ethanol/10 mM phosphate 
buffer at pH 7.0 in the presence or absence of various inhibitory agents. 200 l of each 1-
day-aged PMS-trypsin sample was added to 800 l of a solution containing CR in 5 mM 
phosphate buffer/150 mM NaCl at pH 7.0. Absorption spectra were recorded after 
incubation for 15 minutes at room temperature. Difference spectra were constructed by 
subtraction of spectra of CR alone and PMS-trypsin alone from the spectra of PMS-trypsin 
+ CR. 0.3 mg/ml protein concentration was used for absorption spectra by the successive 
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addition of CR and ginseng extract, and the spectrum of PMS-trypsin was subtracted from 
spectrum of PMS-trypsin + CR. 
 
3.11. Electronic circular dichroism (ECD) measurements 
Electronic circular dichroism spectra were recorded in the far UV range of 185‒260 
nm, in a 0.1 cm pathlength quartz cell on a Jasco J-815 CD spectropolarimeter at 24 
o
C. 
The ECD spectra of PMS-trypsin and PMS-trypsin with diluted inhibitory agents were 
recorded in 60% ethanol/10 mM phosphate buffer (pH 7.0) at 0.15 mg/ml protein 
concentrations. Spectra presented here are the averages of 10 independent scans. Ellipticity 
was expressed in mdeg units. 
 
3.12. Size exclusion chromatography 
Protein samples previously incubated for 1 day were centrifuged at 13,000 rpm for 
1 min, and then 0.5 ml supernatants were applied. Sephadex G-75 column was used for 
size-exclusion chromatography (10 x 300 mm
2
) followed by elution with 0.025 M 
phosphate buffer at pH=7.0. Fractions were collected, and their absorption was measured at 
280 nm. Our column was calibrated with bovine serum albumin (67 kDa), trypsin (23.3 
kDa) and lysozyme (14 kDa). 
 
3.13. Fourier-transformed infrared (FTIR) spectroscopy analysis 
The FTIR spectra were obtained with a Bruker Vertex 70 FTIR spectrometer 
(Bruker, Karlsruhe, Germany). The spectrometer is equipped with a DTGS detector. All 
FTIR measurements were performed under ambient conditions. Typical acquisition 
parameters are listed below: spectral resolution 2 cm
−1
, scan number 32, zero-filling factor 
4, apodization function; Blackman-Harris 3-Term, phase resolution 16, phase correction 
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mode Mertz, aperture 6 mm, scan speed 10 kHz, acquisition mode; double-sided, forward-
backward. The spectrometer is accomplished with a platinum-diamond cell. The spectra 
range was recorded between 4000 cm
-1
 to 900 cm
-1
 with 2 cm
-1
 resolution and 128 scales 
were used to measure each of the samples. 
 
3.14. Transmission electron microscopy 
The inhibitory agent extracts were filtered through 0.02 m Whatman inorganic 
membrane filter before use. 10 l aliquots of the protein samples were placed on carbon-
coated 300-mesh nickel grids (Nisshin EM Co. Ltd. Tokyo) and stained with 2% (w/v) 
uranyl acetate. Electronmicrographs were taken on a JEOL JEM-1011 transmission 
electron microscope (operating at 60 kV), using Olympus Morada 11 megapixel camera 
and iTEM softwer (Olympus). 
 
3.15. Statistical analysis 
Quantitative data was presented as mean +/− standard error of the mean. The 
statistical analysis was made by one-way analysis of variance (ANOVA).  Significance of 
results was determined as ***P ˂ 0.001,**P ˂ 0.01 and *P ˂ 0.05.  
Pearson's correlation coefficient value (r) was defined as: 
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4. Results and discussion 
 In these experiments, trypsin was used as a model protein modified with PMSF. 
The chemically modified enzyme is catalytically inactive, thus there is no autolysis at pH 
7.0. Amyloid-like fibrils were prepared using PMS-trypsin as previously reported by the 
incubation of the soluble protein in the presence of 60% ethanol at 24 
o
C at pH 7.0 
(Kotormán et al., 2015). The turbidity measurement is a procedure for detecting aggregates 
(Zhao et al., 2016). An increase in the UV absorption at 350 nm indicates more protein 
aggregation due to an increase in the scattering of light by aggregated particles (Ghosh et 
al., 2013). The effects of different inhibitory agents on PMS-trypsin aggregation can also 
be monitored via turbidity measurements.  
Congo red is a well-known amyloid-specific dye, when amyloid fibrils are present 
in the solution, the visible absorption intensity increases, and a characteristic red shift of 
the CR absorption band occurs (Chaturvedi et al., 2016). CR exhibits maximal absorption 
at 490 nm. The shoulder peak on the CR absorption spectrum at around 540 nm indicates 
the presence of amyloid fibrils (Mahdavimehr et al., 2017). CR mainly binds to β-pleated 
sheet conformation, especially to amyloid fibrils (Klunk et al., 1989). CR binding assay 
was used to determine whether the aggregated species formed in the PMS-trypsin samples 
were fibril-like or not. CR binding properties of amyloid aggregates have been widely used 
to study anti-fibrillation activity of various inhibitors (Awasthi and Saraswathi, 2016). 
Difference spectra demonstrated the spectral changes of CR upon binding to PMS-trypsin 
amyloid fibrils.  
Amyloid formation and morphology of aggregates were visualized by using 
transmission electron microscopy in the absence and presence of different inhibitory agents 
after 24 h incubation.  
 
 65 
 
4.1. Inhibition of protein aggregation using herbal extracts 
 The sample without inhibitory agent shows maximum absorption value at 350 nm 
whereas the presence of different herbal extracts shows a marked decrease in it. The results 
from this comparative study indicated that peppermint extract displayed the greatest 
amyloid inhibiting function of the 7 samples tested. The maximum decrease of 99.4% in 
the absorption value was found to be in the case of peppermint extract diluted 5 times 
among the herbal extracts. Peppermint was also a good inhibitor of -chymotrypsin 
aggregation (Kotormán et al., 2018). The percentage of inhibition was calculated based on 
turbidity assays. The total phenolic content of the tested herb extracts varied from 163.7 ± 
12.6 to 722.4 ± 25.5 mg GAE/l. The highest amount of total phenolic content was detected 
in the peppermint extract, while it also had the strongest aggregation inhibitory effect 
(Figure 12).  
 
Figure 12. The percentage of inhibition (●) correlates with the total phenolic content 
(o) in the presence of herb extracts diluted x 5. All data were represented as mean ± 
standard error of the mean (SEM) from the average of three independent measurements.  
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The aggregation kinetic assays were used to monitor the time course of aggregation 
by PMS-trypsin through monitoring the increase of absorption at 350 nm in the absence 
and presence of peppermint extract at different concentrations. Faster increase in 
absorption was observed when peppermint extract was not present in the solution. 
Turbidity values were found to decrease continuously with the increasing concentration of 
the peppermint extract and its inhibitory effect was dose dependent (Figure 13). 
 
 
Figure 13. Kinetics of PMS-trypsin fibrillation. Change in OD (A350nm) during PMS-
trypsin fibrillation in the absence (●) and presence of peppermint extract diluted 25 
times (∆) and 50 times (o).  
 
The inhibitory effect of the peppermint extract on the PMS-trypsin fibrillation was 
also observed using CR binding assay. These experiments suggested that the aggregates in 
the absence of an inhibitory agent have amyloid-like properties. In the presence of the 
peppermint extract the value of the maximum of CR differential spectrum was lower than 
in its absence (Figure 14). CR differential spectra indicated that the presence of the 
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peppermint extract decreased the amounts of amyloid fibrils in 60% ethanol at pH 7.0, and 
its inhibitory effect was dose-dependent.  
 
 
 
Figure 14. CR absorption difference spectra of PMS-trypsin in the absence (solid line) 
and presence of peppermint extract x 25 (dotted line) and x 50 (dashed line). CR and 
protein final concentrations were 3.2 M and 26 g/ml, respectively. 
 
TEM image of PMS-trypsin in the absence of the peppermint extact shows fibrillar 
structure in 60% ethanol at pH 7.0 (Figure 15A). However, in the sample in which 
inhibitory agent was added to the PMS-trypsin, there was a significant lack of fibrils with 
only occasional scattered amorphous aggregates were observed (Figure 15B). TEM images 
demonstrated, that peppermint extract had inhibitory effect on the formation of amyloid-
like fibrils of PMS-trypsin.  
Based on our results, it was found that the anti-amyloidogenic effects of the herbal 
extracts could be related to their total phenolic content. Our results showed that the 
peppermint extract had a preventive effect on aggregation of the PMS-trypsin, and it could 
effectively inhibit the in vitro fibrillation. The process depended on the amount of the 
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peppermint extract. Peppermint is, therefore, a valuable source of phenolic compounds to 
prevent fibril formation. 
 
 
 
 
 
  A                                                                      B              
Figure 15. Transmission electron micrographs of PMS-trypsin in the absence (A) and 
presence (B) of peppermint extract diluted 25 times. The scale bar indicates 500 nm. 
Enzyme concentration: 0.13 mg/ml. 
 
4.2. Inhibitory effect of the chili extract on the amyloid-like fibril formation 
Turbidity measurement was used as an indication of the degree of aggregation in 
the presence of 27 commercially available spices. All examined agents showed varied 
effects. These experiments revealed that among the spices investigated chili was the best 
inhibitor. In the presence of chili extract diluted 500 times, the absorption had decreased to 
36.8% relative to the sample not containing inhibitory agent (Figure 16).  
Aggregation kinetic assays were performed in the absence and presence of various 
concentrations of the chili extract. Turbidity values were found to decrease continuously 
with the increasing concentrations of the chili extract. The results are shown in Figure 17. 
Our experiments proved, that the inhibitory effect of the chilli extract was dose dependent. 
The CR absorption difference at 550 nm was found to decrease with incubation in 
the presence of chili extract. CR binding assay indicated that the presence of the chili 
extract decreased the amounts of amyloid-like fibrils, and inhibited the fibril formation 
dose-dependently (Figure 18).  
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Figure 16. Turbidity changes of PMS-trypsin in the presence of various spice extracts 
or without them. In the incubation samples the spice extracts were diluted 500 times.  
 
 
Figure 17. Time course of PMS-trypsin aggregation in the absence (●) and presence 
of chili extract diluted 50 times (□), 500 times (∆) and 1,000 times (o).  
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Figure 18. CR differential spectra in the absence (solid line) and presence of chili 
extract diluted 250 times (dotted line) and 1000 times (dashed line). CR and protein 
final concentrations were 3 M and 26 g/ml, respectively. 
 
FTIR spectroscopy has been used since early 1970 to examine the amyloid fibril 
structure (Sarroukh et al., 2013). The fibrils display a typical anti-parallel β-sheet structure 
characterized by two bands in the amide I: a low frequency, high intensity band around 
1620–1630 cm−1 and a high frequency, low intensity band located around 1685–1695 cm−1. 
In order to demonstrate the inhibitory effect of chili extract on PMS-trypsin fibrillation by 
structural change, we analysed the FTIR spectrum of protein in 10 mM phosphate-buffered 
60% ethanol without chili extract and in the presence of chili extract diluted 500 times. A 
characteristic peak of 1629 cm
−1
 was obtained when it was measured with the PMS-
trypsin, which shows the oligomers have anti-parallel β-sheet organization. 1648, 1641 
cm
−1
 strong peaks (Figure 19) were obtained in the presence of chili extract with PMS-
trypsin, which clearly shows a change in structural orientation and the transition state of 
oligomers to a monomer one. It also indicates that the chilli extract inhibited amyloid 
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aggregation by stabilizing its native form from aggregating and remodelling or degrading 
toxic amyloid oligomers. 
 
 
Figure 19. FTIR spectra of PMS-trypsin in 10 mM phosphate-buffered 60% ethanol 
illustrating the Amide I regions respectively in the presence of chili extract diluted 
500 times and without it. 
 
Electronic circular dichroism analysis in the far UV wavelength range (185–260 
nm) was conducted to determine the changes in the secondary structure of PMS-trypsin in 
aqueous ethanol at pH 7.0. The presence of a mild solvent causes an increase in the β-sheet 
conformation in proteins (Furkan et al., 2016). Conversion of the secondary structure of 
PMS-trypsin in the presence of 60% ethanol takes place immediately. It is known from our 
research group’s previous experiments that in the presence of 10 mM phosphate buffer at 
pH 7.0 in the structure of the PMS-trypsin, α-helix is present with the dominance of the β-
sheet. The ECD spectrum obtained in the presence of 60% ethanol was characteristic of 
amyloid fibrils (Kotormán et al., 2015). Differences between the measured spectra arise 
from the differences in size distribution of the aggregates evolving gradually. The spectra 
were detected placing the cell in two ways, in the middle of the sample holder or next to 
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the detector. The two measurements give the same results with clear, real solution. A 
remarkable change can be observed in the sample without any inhibitory agent concerning 
the intensity and blue shift of spectral maxima for the sample closer to the detector. In the 
absence of chili extract, the large sized colloid aggregates were abundant. The light-
dispersion of such colloidal samples is substantial, consequently fewer photons get to the 
detector, which results in the acquisition of less intense spectra. Furthermore, the 
concentration of proteins in real solution state is lower in suspensions that also contribute 
to the decrease of spectral intensities. We observed a remarkable change in the intensity of 
the spectrum and a blue shift approaching the sample toward the detector without any 
inhibitory agent. This sample contained the largest-sized aggregates. The two 
measurements gave almost the same results in the presence of chili extracts diluted 500 
times indicating that the chili extract stabilized the protein in a more or less dissolved state 
(Figure 20).  
 
 
 
Figure 20. ECD spectra of PMS-trypsin in 60% ethanol without chili extract (solid 
line, dashed line) and in the presence of chili extract diluted 500 times (dotted-dashed 
line, dotted line). The sample was set in the middle of the sample holder (solid line, dotted 
line), or next to the detector (dashed line, dashed-dotted line).  
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Presumably, the structure of the protein slightly changes in the presence of a chili extract, 
too, but aggregates do not. If they do, they form rather slowly, indeed. 
The ability of chili extract to prevent aggregation was visualised by TEM. TEM 
image of PMS-trypsin in absence of chili extract shows fibrillar structure in 60% ethanol. 
However, in the sample in which chili extract was added to the PMS-trypsin, there was a 
significant lack of fibrils with only occasional scattered amorphous aggregates (Figure 21). 
The finding suggests that chili bioactive compounds may be potential therapeutic drug 
candidates. 
 
  A      B  
Figure 21. Transmission electron micrographs of PMS-trypsin (A) in the absence and 
(B) in the presence of chili extract x 500. The scale bar indicates 500 nm. Enzyme 
concentration: 0.13 mg/ml. 
 
 
4.3. Examination of the anti-amyloidogenic effect of the P. ginseng extract 
When I joined this research group’s work, experiments on the anti-amyloidogenic 
effect of the P. ginseng extract had already been underway. To find out whether its 
bioactive components and CR compete to bind to the amyloid-like fibrils, or not, we 
successively added CR and the ginseng extract to the fibrils. During the first experiment, 
CR was firstly added to the fibrils, followed by the P. ginseng extract. In the second one, 
the sequence of administration of these agents was reversed. With these experiments we 
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could show that there is no competition between the CR and the biomolecules of the P. 
ginseng extract to bind to the fibrils or to a different site (Figure 22).  
 
 
 
Figure 22. CR absorption spectra by successive addition of CR and ginseng extract. 
CR alone (solid line), in the absence of P. ginseng extract (dashed-dotted line), first 
adding CR and then the ginseng extract to the protein (dashed line), and the reverse 
order (dotted line). 
 
The different-sized particles in our samples were selected using size exclusion 
chromatography. Our results proved that the sample without P. ginseng extract contains 
higher amounts of protein oligomers than in the presence of it (Figure 23). In the presence 
of P. ginseng extract there are more monomer trypsin molecules in the sample. Our results 
show that the presence of ginseng extract helps at maintaining the native structure of the 
protein. It was demonstrated that ginsenoside Rg1 and Rb1 stabilize the derivative of κ-
casein in its native-like state (Liu et al., 2015).  
ECD spectroscopy was used to examine the conformational changes of PMS-
trypsin in 60% ethanol/10 mM phosphate buffer, in the presence and in the absence of the 
500-fold diluted P. ginseng extract. ECD experiments were made in two different sample 
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positions. Significant change can be observed in the sample without the P. ginseng extract 
concerning the intensity and blue shift of spectral maxima for the sample closer to the 
detector. Adding P. ginseng extract to our sample decreased the light dispersion of the 
enzyme solution (Figure 24). This is due to the decrease of the rate of the protein 
aggregation or to the smaller size of the aggregates evolved. Although, the intensity of 
spectral minima varies in the presence of P. ginseng extract, a greater shift of the minima 
cannot be observed.  
 
 
Figure 23. Molecular weight determination using Sephadex G-75 column in the 
presence of P. ginseng extract x 100 (solid line) and without it (dashed line). 
 
The effects of the P. ginseng extract on morphology of PMS-trypsin fibrils were 
further studied by TEM (Figure 25). TEM micrographs confirmed the formation of 
amyloid-like fibrils without the inhibitory agent in aqueous ethanol at pH 7.0 after 
incubation for 24 hours. However in the presence of the 500-fold diluted P. ginseng 
extract, TEM image demonstrated that fibril formation was effectively inhibited. 
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Figure 24. ECD spectra of PMS-trypsin in 10 mM phosphate-buffered 60% ethanol 
with P. ginseng extract x 500 (dotted-dashed line, dotted line) or without it (solid line, 
dashed line). The sample was set in the middle of the sample holder (solid line, dashed-
dotted line), or next to the detector (dashed line, dotted line). 
 
 
 
 
 
A                                                                        B 
Figure 25. TEM micrographs of PMS-trypsin samples after incubation at 24°C for 24 
h. PMS-trypsin in 60% ethanol (A), PMS-trypsin in 60% ethanol in the presence of P. 
ginseng extract x 500 (B). The scale bar indicates 500 nm. Enzyme concentration: 0.13 
mg/ml. 
 
4.4. Inhibition of amyloid-like fibril formation using the Eduscho coffee extract  
The turbidity measurements were performed to detect the effect of different coffee 
extracts on PMS-trypsin aggregation. The greatest effect was exerted by the Eduscho 
coffee extract. The absorption had decreased in the presence of Eduscho coffee extract 
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diluted 250 times to 18.1% relative to the sample not containing inhibitory agent. The total 
concentrations of phenolic compounds of different coffee extracts ranged from 4942 ± 
361.7 to 7702 ± 528.5 mg GAE/l (Figure 26). The calculated Pearson’s correlation 
coefficient values (r), fell in between 0.896 and 0.997. According to our experiments, the 
degree of inhibition changed pro rata with the total concentrations of phenolic compounds.  
 
 
Figure 26. The change of percentage of inhibition (●) with the total phenolic content 
(o). Coffee extracts were diluted x 250. All data were presented as mean ± standard error 
of the mean (SEM) from three independent measurements. 
 
 
CR binding assay can also be utilised to study the anti-fibrillation efficiency of 
small molecular inhibitors (Awasthi and Saraswathi, 2016). CR binding assay indicated 
that the presence of the Eduscho coffee extracts decreased the amounts of amyloid fibrils in 
60% ethanol at pH 7.0, and their inhibitory effects were dose-dependent (Figure 27). 
Similar to our experimental results, Cheng et al. came to the conclusion that coffee 
components had inhibited the amyloid fibril formation using human islet amyloid 
polypeptide (Cheng et al., 2011). 
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Figure 27. CR difference spectra without coffee extract (solid line) and in the 
presence of Eduscho coffee extract diluted 250 times (dotted line) and 500 times 
(dashed line). Congo red and protein concentrations were 5 M and 26 g/ml, 
respectively. 
 
 
To determine whether there is a competition between polyphenolic compounds of 
the Eduscho coffee extract and CR in the binding to the PMS-trypsin fibrils, we used the 
successive addition of the coffee extract and CR (Figure 28). During the first experiment, 
first CR, then the coffee extract was added to the amyloid-like fibril. In the second 
experiment the administration of these agents happened in reverse order. With these 
experiments we could show that the polyphenols in the coffee extract do not bind to the 
fibrils or the polyphenolic compounds bind to another site. 
Gel filtration chromatography was used to separate the particles of different size. 
The presence of Eduscho coffee extract diluted 100 times increased the amount of the 
protein oligomers (Figure 29). We demonstrated that the inhibitory effect of the coffee 
extract on the fibril formation is due to its capacity to stabilize the oligomeric form of the 
PMS-trypsin. Similarly to our results, phenyl ethyl alcohol had had an inhibitory effect on 
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hen egg white lysozyme fibril formation by producing mainly oligomers (Seraj et al., 
2018). 
 
Figure 28. Absorption spectra by successive addition of CR and Eduscho coffee 
extract. CR alone (solid line), in the absence of Eduscho coffee extract (dashed-dotted 
line), first adding CR and then the Eduscho coffee extract to the protein (dotted line), 
and the reverse order (dashed line). 
 
 
 
Figure 29. Size-exclusion chromatography using Sephadex G-75 column in the 
presence of Eduscho coffee extract x 100 (solid line) and without it (dashed line). 
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 ECD spectra of PMS-trypsin were recorded at lower ethanol concentrations, in an 
attempt to follow the gradual conversion of the secondary structure preceding 
intermolecular association. Spectra were measured after 0, 20, 30, 60, and 120 min 
incubation in 10% ethanol/0.01 M phosphate buffer at pH 7.0. In general, spectra measured 
at 10% ethanol concentration display minor α-helical contributions as opposed to those 
measured at 60% ethanol concentration, where spectral characteristics of β-sheet structure 
are dominant (Kotormán et al., 2015). In 10% ethanol/0.01 M phosphate buffer the 
intensity of the shoulder appearing at 200 nm was found to increase to some extent over 
time, while the shoulder around 218 nm have diminished (Figure 30). ECD spectral 
changes were complete after 60 min incubation. These experimental results indicated slow 
helix to coil transition, which could be elucidated as the first structural transitional step of 
the trypsin aggregation process.  
 
 
Figure 30. ECD spectra of PMS-trypsin in 10 mM phosphate-buffered 10% ethanol 
without coffee extract at 0 min (solid line), 20 min (dotted-dashed line), 30 min 
(dashed line), 60 min (dotted line).  
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Such structural changes were found to be slower and less pronounced in the presence of 
the Eduscho coffee extract diluted 250 times (Figure 31). Taking these results into account, 
we concluded that the addition of the Eduscho coffee extract effectively prevented PMS-
trypsin from undergoing helix-to-coil transition. 
 
 
Figure 31. ECD spectra of PMS-trypsin in 10 mM phosphate-buffered 10% ethanol 
in the presence of Eduscho coffee extract x 250 at 0 min (solid line), 20 min (dotted-
dashed line), 30 min (dashed line), 60 min (dotted line), 120 min (double-dotted-
dashed line).  
 
ECD spectroscopy in the far UV wavelength range (185–260 nm) was used to 
detect the secondary structural changes in PMS-trypsin in 60% ethanol in the absence and 
presence of the Eduscho coffee extract. The sample was either set in the middle of the 
sample compartment, or at the right side, next to the detector (Figure 37). A change in the 
intensity and blue shift was observed, when the sample was located next to the detector. 
This indicated that large aggregates were present in the protein sample without the 
Eduscho coffee extract. Such a phenomenon was observed to a lesser extent when the 
Eduscho coffee extract was present in the samples. 
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Figure 37. ECD spectra of PMS-trypsin in 60% ethanol without Eduscho coffee 
extract (solid line, dashed line) and in the presence of Eduscho extract diluted 250 
times (dashed-dotted line, dotted line). The sample was set in the middle of the sample 
holder (solid line, dotted line), or next to the detector (dashed line, dashed-dotted line).  
 
Amyloid formation and morphology of aggregates were visualized by using TEM. 
TEM images of PMS-trypsin in absence of inhibitory agent show fibrillar structure in 60% 
ethanol at pH 7.0 (Figure 38A and 39A). The extent of fibril formation was reduced at a 
significant level in the presence of the Eduscho coffee extract diluted 250 times (Figure 
39B). 
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Figure 38. Transmission electron micrograph of PMS-trypsin in the absence (A) and 
the presence of the Eduscho coffee extract dikuted 250 times (B). The scale bar 
indicates 500 nm. Enzyme concentration: 0.13 mg/ml. 
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Figure 39. Transmission electron micrograph of PMS-trypsin in the absence (A) and 
the presence of the Eduscho coffee extract dikuted 250 times (B). The scale bar 
indicates 10 m. Enzyme concentration: 0.13 mg/ml. 
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4.5. Inhibitory effect of the grapefruit seed extract on the amyloid-like fibril 
formation 
The grapefruit seed extract diluted 800 times reduced the absorption to 52.3% 
compared relative to the PMS-trypsin sample, which contained no inhibitory agent, so, it 
was the best inhibitor among the food supplements investigated. The total phenolic content 
of the different inhibitory agents was determined, and it varied between 431.4 ± 62.2 and 
2659 ± 59.9 mg GAE/l (Figure 40). The percentage of inhibition of amyloid formation did 
not change proportionally with the total phenolic content. Based on the results obtained, it 
is probable that not only polyphenols are responsible for the fibril formation inhibitory 
effect but also other compounds. Grapefruit seed extract also contains limonoids (Cvetnić 
and Vladimir-Knezević, 2004), which have neuroprotective effects (Venkatesan et al., 
2015; Yoon et al., 2010).  
 
Figure 40. Change of the total phenolic content (o) with the percentage of the 
inhibition of amyloid-like fibril formation (●) in 60% ethanol in the presence of 
different inhibitory agents x 800. All data were presented as mean ± standard error of the 
mean (SEM) from three independent measurements. 
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The limonin concentration in the grapefruit seed extract was determined: it was 16.8 ng/ml. 
In acai commercial pulps there are various bioactive compounds, in addition to phenolic 
compounds and there are also carotenoids in them (Santos et al., 2008). Some carotenoids 
have anti-amyloidogenic effect (Lakey-Beitia et al., 2017).  
The inhibitory effect of the grapefruit seed extract on the aggregation process was 
determined at various concentrations. At 100-fold dilution grapefruit seed extract almost 
eliminated the formation of protein aggregates. The anti-aggregation effect of the 
grapefruit seed extract was dose dependent (Figure 41). 
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Figure 41. Turbidities at 350 nm of PMS-trypsin in 60% ethanol at pH 7.0 in the 
absence or presence of different concentrations of grapefruit seed extract. 
 
To determine the efficiency of the grapefruit seed extract and of limonin against the 
PMS-trypsin fibrillation CR binding assay was used. Both inhibitory agents were able to 
exert dose-dependent inhibitory effect on the formation of amyloid-like fibrils (Figure 42 
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and 43). For the first time, our results indicated that limonin was an effective anti-
amyloidogenic agent. 
 
Figure 42. CR absorption difference spectra of PMS-trypsin in the absence (solid line) 
and presence of grapefruit seed extract diluted 800 times (dashed line) and 100 times 
(dotted line). Congo red and protein concentrations were 6 M and 26 g/ml, respectively. 
 
 
 
 
Figure 43. CR absorption difference spectra of PMS-trypsin in the absence (solid line) 
and presence of 34 nM limonin (dashed line) and 340 nM limonin (dotted line).  
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Changes in the PMS-trypsin secondary structure can be revealed using far-UV 
ECD measurements in 60% ethanol in the absence or presence of grapefruit seed extract 
diluted 500 times. Far-UV ECD measurements were made in two different sample 
positions. In the presence of grapefruit seed extract light dispersion decreased (Figure 44). 
This can be explained by the fact that the aggregation speed has decreased, or the size of 
the aggregates formed has decreased. According to our experiments, the grapefruit seed 
extract effectively inhibited the amyloid fibril formation. 
 
 
Figure 44. Far-UV CD spectra of PMS-trypsin in the absence (dashed line, solid line) 
and presence of grapefruit seed extract x 500 (dotted-dashed line, dotted line). The 
sample was set in the middle of the sample holder (solid line, dotted line), or next to 
the detector (dashed line, dotted-dashed line). 
  
 
TEM studies showed that there was no fibril formation in the presence of grapefruit 
seed extract diluted 500 times, indicating the inhibitory effect of grapefruit seed extract on 
the formation of amyloid-like fibrils by trypsin (Figure 45). 
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Figure 45. Transmission electron micrographs of PMS-trypsin samples in the absence (A) 
and presence (B) of grapefruit seed extract diluted 500 times in 60% ethanol at pH 7.0. 
Protein concentration: 0.13 mg/ml. The scale bar represents 500 nm. 
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5. Conclusions 
The present study can be concluded by the statement that natural product extracts 
may be efficient anti amyloidogenic agents, as they arrest PMS-trypsin fibrillation in a 
concentration dependent manner. We summarize the most important findings of our study 
as follows: 
 It has been demonstrated that the peppermint extract could effectively inhibit PMS-
trypsin amyloid fibril formation in vitro, and the process was concentration 
dependent of the peppermint extract. Our findings revealed that the anti-
amyloidogenic activities of herb extracts might be related to their total phenolic 
contents. According to our experiments peppermint extract might serve as a 
valuable source of beneficial phenolic compounds for the prevention of protein 
aggregation. 
 Our study demonstrated that the chili cayenne extract got the highest inhibitory 
effect on the formation of amyloid fibrils among all the spices investigated. The 
findings also suggest that the bioactive compounds in the chili extract may be a 
potential therapeutic drug candidate for amyloid related and neurodegenerative 
diseases including Alzheimer’s disease. This study concludes that the possible 
nutritional importance of kitchen spices in the food system and the inhibitory 
effects of the chili extract clearly indicate that they could be used as a 
pharmacological agent to inhibit or retard amyloid fibril formation in Alzheimer’s 
disease. 
 The present study revealed that the P. ginseng extract is an efficient anti-
amyloidogenic agent against PMS-trypsin fibrillation in aqueous ethanol at pH 7.0. 
Our results showed that the presence of the P. ginseng extract helped to maintain 
the native structure of the protein. 
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 According to our experiments, the degree of inhibition was found to change pro 
rata with the total concentrations of phenolic compounds of the coffee extracts. It 
can be concluded that the Eduscho coffee extract may be an effective anti-
amyloidogenic agent, as it arrests PMS-trypsin fibrillation in a concentration 
dependent manner. 
 We have successfully shown that the grapefruit seed extract inhibits the 
aggregation process of PMS-trypsin in 60% ethanol at pH 7.0. The inhibition of 
PMS-trypsin aggregation positively correlated with increased grapefruit seed 
extract concentration. Our results indicated, for the first time, that limonin 
effectively inhibited fibril formation. 
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8. Summary  
Background 
 Amyloid aggregation is a hallmark of several central nervous system neurological 
disorders including neuro development diseases affecting brain and peripheral tissues. The 
formation of insoluble amyloid is associated with a number of fatal neurodegenerative 
diseases such as Alzheimer’s, Parkinson’s, Huntington’s diseases, or type II diabetes 
mellitus, transmissible spongiform encephalopaty, cerebellar ataxias and primary and 
secondary systemic amyloidosis. Amyloid formation is a generic form of a polypeptide 
conformation and most proteins have a potential to form amyloid-like structure under 
appropriate conditions. The core structure of the fibrils is stabilized by hydrogen bonding 
between atoms of the polypeptide backbone. Despite different proteins being responsible 
for each disease, all of them share similar features including beta-sheet-rich secondary 
structures and fibril-like protein aggregates. 
Prevention is a more effective strategy than the treatment of chronic diseases. 
Functional foods that contain significant amounts of bioactive components play important 
roles in the prevention of chronic diseases. Unfolded or partially unfolded proteins 
associate with each other to form small, soluble aggregates that undergo further assembly 
into protofibrils or protofilaments and then into mature fibrils, which is associated with 
increasingly common and highly debilitating diseases. The amyloid diseases involve 
predominantly the aggregation of specific proteins, but fibrils can be formed by many other 
peptides and proteins too. Natural phenolic compounds, a wide panel of plant molecules, 
are one of the most actively investigated categories of potential amyloid inhibitors. One 
therapeutic approach is the screening or development of natural bioactive molecule 
inhibitors of Aβ aggregation. Dietary natural products are a rich source of phytochemicals 
and active compounds, which have the potential for future drug development for AD. In 
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the last decade, researchers have reported that certain fruits, vegetables, spices, drinks and 
beverages can potentially counteract AD pathogenesis. These natural products are effective 
at inhibiting oxidative stress, Aβ accumulation and toxicity, tau phosphorylation, and 
neuro-inflammation and exhibit antioxidant and anti-inflammatory properties. Researchers 
are currently searching for new, safer and more effective therapies that can target the 
pathophysiology of AD more precisely and inhibit the Aβ accumulation and toxicity. 
 
Aims 
 Our primary interest here was to discover novel molecules possessing anti-
neurodegenerative and anti-amyloidogenic properties through the screening of a diverse 
library of natural compounds. By considering these main objectives, our aims were: 
 Collection, extraction of bioactive compounds and total phenolic compound 
analysis from screened categories or groups of natural products. 
 Modification of trypsin with phenylmethylsulfonyl fluoride (PMSF) for the 
formation of amyloid-like fibrils in aqueous organic solvents. 
 In vitro inhibitory screening by turbidity, size exclusion chromatography, 
aggregation kinetics, CR binding, FTIR, HPLC-MS, CD and TEM on amyloid-like 
fibril formation of trypsin by natural product extracts in aqueous organic ethanol. 
 Selection of suitable therapeutic agents for amyloid related neurodegenerative 
diseases.  
 
Materials and methods 
To address the above questions we chose the following specific methods like 
preparation of the extracts, assay of enzyme activity, modification of trypsin with 
phenylmethylsulfonyl fluoride (PMSF), turbidity measurements, determination of the total 
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phenolic content, aggregation kinetics, CR binding, HPLC-MS, ECD measurements, size 
exclusion chromatography, FTIR spectroscopy analysis, transmission electron microscopy, 
which can address the inhibitory activity of natural product extracts on amyloid-like fibril 
formation of trypsin in aqueous organic solvents like in 60% ethanol at pH 7.0. 
 
Results and discussion 
 Recent studies on Aβ amyloid formation indicate that several natural small aromatic 
compounds and flavonoids interfere with aggregation pathways possibly by remodelling 
the amyloid intermediates through the different mechanisms or interactions. The effects of 
different inhibitory agents on PMS-trypsin aggregation can also be monitored via turbidity 
measurements. The total phenolic content of the different inhibitory agents was 
determined, and it varied between 163.7 ± 12.6 and 7,702 ± 528.5 mg GAE/l. By using 
HPLC-MS, we determined that the limonin concentration of the grapefruit seed extract was 
16.8 ng/ml. The aggregation kinetic assays were used to monitor the time course of 
aggregation by PMS-trypsin through monitoring the increase of absorption at 350 nm in the 
absence and presence of various inhibitory agents at different concentrations. 
The Congo red absorption difference at 550 nm was found to decrease with 
incubation in the presence of inhibitory agents. With the size-exclusion chromatography 
analysis experiment we demonstrated that the inhibitory effect of the Eduscho coffee 
extract on the formation of amyloid-like fibrils is due to its capacity to stabilize the 
oligomeric form of the protein. FTIR result indicates that the chilli extract inhibited 
amyloid aggregation by stabilizing the native form of the protein by aggregating and 
remodelling or degrading toxic amyloid oligomers. Electronic circular dichroism analysis 
concludes that the addition of some natural product extract is effective in preventing PMS-
trypsin from undergoing helix-to-coil transition. TEM images demonstrated, that the 
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Eduscho coffee, chili, P. ginseng, grapefruit seed and peppermint extracts had inhibitory 
effect on the formation of amyloid-like fibrils of PMS-trypsin. The extent of fibril 
formation was reduced at a significant level in their presence. 
The present study concludes that the natural product extracts like the coffee, chili, 
P. ginseng, grapefruit seed and peppermint extracts may be efficient anti-amyloidogenic 
agents, as they arrest PMS-trypsin fibrillation at 60% ethanol at pH 7.0 in a concentration 
dependent manner. 
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9. Összefoglalás 
Az amiloid fibrillumok jelenléte számos nem kívánatos betegségre jellemző. 
Ilyenek pl. az Alzheimer-, a Parkinson-, a Hungtinton kór, a prion betegségek és a 2-es 
típusú cukorbetegség (diabetes mellitus) is, melyek világszerte milliók életét keserítik meg. 
Az amiloid fibrillumok olyan fibrilláris fehérje aggregátumok, melyek a -lemez 
szerkezetű polipeptidláncok egymás mellé rendeződése révén jönnek létre. A 
fibrillumokban a -lemezek a fibrillumok hossztengelyeire merőlegesen orientálódva 
helyezkednek el. A fibrillumokat az egymás mellett lévő peptid-gerincek megfelelő 
atomjai között kialakuló hidrogénhíd kötések sokasága stabilizálja. Fibrillumképzésre 
bizonyos enyhe denaturáló körülmények mellett valamennyi fehérje képes lehet. Az 
amiloid fibrillumok hosszú, vízben nem oldódó, elágazások nélküli képződmények. 
Keletkezésük szigmoid alakú görbével jellemezhető, melyben a kezdeti lassú lag fázist 
gyors aggregáció követ, majd a folyamat telítési szakasszal zárul. A lag fáziban olyan 
magok jönnek létre, melyek monomerek hozzáadásával fibrillumokká alakulnak. Némely 
festékek, mint pl. a kongóvörös vagy a tioflavin T, nagy affinitással képesek az amyloid 
fibrillumokhoz kötődni, melyet jellemző spektrális változások kisérnek, így lehetővé téve a 
fibrillumok jelenlétének érzékeny detektálását. 
Mivel a fehérje konformációs betegségekben szenvedők száma évről-évre 
folyamatosan emelkedik, rendkívül fontos a megelőzésük. A krónikus betegségek 
megelőzése eredményesebb lehet, mint a kezelésük. Napjainkban számos olyan törekvés 
van, mely különböző, növényekben előforduló biomolekulák felhasználásával igyekszik 
kivédeni az amiloid fibrillumok keletkezését. A már igen rég óta széles körben használt 
illetve fogyasztott fűszerekben, étrend kiegészítőkben, kávékban, teákban, borokban, 
gyümölcsökben és zöldségekben jelen lévő bioaktív vegyületek fontos szerepet játszhatnak 
(nem kívánatos mellékhatások nélkül) a különböző amiloidózisok megelőzésében, illetve a 
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tüneteik enyhítésében. A bennük jelen lévő polifenolos vegyületek jótékony hatása részben 
annak köszönhető, hogy képesek stabilizálni a fehérjék natív szerkezetét, illetve aromás 
gyűrűik révén olyan speciális aromás-aromás kölcsönhatások kialakítására képesek, 
melyek segítségével gátolni tudják a fibrillumok létrejöttét. Jelenleg több, mint 8000 
növényi polifenolt ismerünk. Közülük számos vegyület, mint pl. a kurkumin, a galluszsav 
és a rezveratrol anti-amiloidogén hatását már leírták. Az amiloid fibrillumok gátlásában 
nem polifenolos vegyületek is részt vehetnek. 
Kísérleteinkben különböző növényi kivonatok amiloid-szerű fibrillum képződést 
gátló hatását vizsgáltuk modell fehérjeként fenil-metil-szulfonil fluoriddal (PMSF) 
kémiailag irreverzibilisen módosított, inaktivált tripszint használva, 60 %-os etanolos 
közegben pH 7,0-nél. Munkánk célja volt a kereskedelmi forgalomban lévő különböző 
gátló ágensek hatékonyságának összehasonlítása. Az általunk megvizsgált fűszerek közül a 
chili, a teák közül a borsmenta, az étrend kiegészítők közül a grapefruit mag kivonat, 
valamint a kávék közül az Eduscho kávé bizonyult a leghatékonyabb inhibitornak. A kávék 
és teák esetében korrelációt találtunk az összes polifenol tartalmuk és az aggregátum 
képződést gátló hatásuk között. Kongó vörös kötődési kísérletekkel kimutattuk a grapefruit 
mag-, a chili-, a borsmenta- és az Eduscho kávé kivonatainak koncentrációtól függő 
mértékű gátló hatását. A grapefruit mag kivonatban is jelen lévő limoninról először írtuk 
le, hogy anti-amiloidogén hatással rendelkezik. Az Eduscho kávé és a ginseng 
kivonatokról megállapítottuk, hogy nincsen versengés a kongóvörös és a gátló ágensek 
biomolekulái között a fibrillumokhoz való kötődésben, illetve lehetséges az is, hogy más-
más felületi helyekhez kötődnek. Méret kizárásos kromatográfia felhasználásával 
kimutattuk, hogy a Panax ginseng kivonat a PMS-tripszin monomer formáját, míg az 
Eduscho kávé az oligomer formát stabilizálja. Fourier-transzformációs infravörös 
spektroszkópiai analízissel bizonyítottuk, hogy a chili kivonat a natív forma stabilizálása 
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révén gátolja a PMS-tripszin aggregációját. Elektronikus cirkuláris dikroizmus 
spektroszkópiai elemzéssel fény derült arra, hogy az Euscho kávé kivonat megakadályozza 
a fehérjében lévő -hélix szerkezeteknek a rendezetlen szerkezetűekké alakulását ez által 
gátolva a fibrillációt. Kimutattuk, hogy a chili extraktum jelenléte stabilizálta a PMS-
tripszin oldott állapotát. Feltételezhető, hogy közben a fehérje szerkezetete kis mértékben 
megváltozott ugyan, de az aggregátumok egyáltalán nem, vagy csak nagyon lassan tudnak 
kialakulni. A különböző gátló ágensek fibrillum képződésre kifejtett jótékony hatását 
transzmissziós elektron mikroszkópos felvételekkel is alátámasztottuk. 
Kísérleti eredményeink alapján megállapítható, hogy az Eduscho kávé, a chili, a P. 
ginseng, a grapefruit mag és a borsmenta kivonatai hatékony anti-amiloidogén ágensek a 
PMS-tripszin aggregációjában pH 7,0-nél. 
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